Dr. Reddy’s Laboratories, SA  PPC-06-CD-004 
Study Tit
le: A Randomized, D ouble -Blind, P lacebo- Controlled, 
Multicenter, 24 -Week Study to Assess the Efficacy and 
Safety of PPC-06 ( Tepilamide F umarate) Extended 
Release Tablets in Subjects with Moderate-t o -Severe 
Plaque Psoriasis (AFFIRM Study) 
Dr
ug Name/Dosage: PPC-06/400 mg QD, 400 mg BID, 600 mg BID 
Protocol No: PPC-06-CD-004 
IND No:  120973 
Development Phase:  2 
Document Status, Date: 26 October  2018 
Document V ersion:  
Previo
us Version: V3.0, Amendm
ent 2 
V2.0, Amendm
ent 1, 30 May 2018 
Original Protocol 25 October 2017 
Sponsor:  D
r Reddy’s Laboratories, SA  
Elisabethenanlage 11 
CH-4051 Basel 
Switzerland  
Sponsor  Agent : Dr Reddy’s Laboratories,  Inc. 
107 College Road East Princeton, NJ 08540 
Propert
y of Dr. Reddy’s Laboratories, SA 
Confidential 
The confidential information provided in this document is for use by parties directly involved in this 
investigation. By accepting this document,  you agree that the information contained herein will not be 
disclosed to any person not directly involved in this investigation without written authorization from 
Dr. Reddy’s Laboratories, SA  
Dr. Reddy’s Laboratories , SA 
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
- 3 - SIGNATURE PAGE FOR INVESTIGATOR(S) 
Produ
ct: PPC -06 ( Tepilamide Fumarate ) Extended Release Tablets  
Protocol N umber:  PPC -06-CD-004 
Protocol T itle: A Randomized, Double -Blind, Placebo -Controlled, Multicenter, 
24-Week Study to Assess the Efficacy and Safety of PPC -06 
(Tepilamide Fum arate) Extended Release Tablets in Subjects with 
Moderate -to-Severe Plaque Psoriasis  
The signature of the study investigator below constitute s his/her approval of this protocol and 
provides the necessary assurances that this study will be conducted according to all 
stipulations, clinically and administratively, as detailed in the protocol. It is agreed that the conduct and results of this study will be kept confidential.  
COMPLIANCE  
STATEMENT  
The study will be carried out in accordance with  Good Clinical P ractice (GCP) as required b y 
the United States (US) Code of Federal  Regulatio ns (CFR) applicable to  clinical studies 
(45 CFR Part 46; 21 CFR Part  50, 21 CFR  Part 56, and 21 CFR Part  312) and ICH E6; 62 
Federal Register 25691 (1997). 
SIGNATURES  
The signatures below provide the necessary assur ances that this trial will be conducted 
according to all stipulations of the protocol, including all statements regarding  
confidentiality, and according to local legal and regulatory  requirements  and applicable 
US federal regulations and ICH guidelines.  
Principal Investigator ’s printed name  
Principal Investigator ’s signature  Date 
Dr. Reddy’s Laboratories , SA 
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
- 4 - TABLE OF CONTENTS  
TABLE OF C
ONTENTS  ..............................................................................................................4  
LIST OF TABLES  .........................................................................................................................7  
LIST OF FIGURES  .......................................................................................................................8  
LIST OF ABBREVIATION S AND DEFINITION OF TERMS  ...............................................9  
1. SYNOPSIS  ..........................................................................................................................12
2. INTRODUCTION ..............................................................................................................21
2.1 Plaque Psoriasis  ........................................................................................................21  
2.2 Fumaric Acid Esters  .................................................................................................22  
2.3 Investigational Product .............................................................................................22  
2.4 Rationale of the Study ..............................................................................................23  
3. TRIAL OBJECTIVES AND PURPOS E ..........................................................................24
4. STUDY DESIGN ................................................................................................................24
4.1 Overall Study Design  ...............................................................................................24  
4.2 Study Endpoints  .......................................................................................................26  
4.2.1  Efficacy Endpoints .......................................................................................26  
4.2.2  Health Outcome/Quality of Life Endpoints  .................................................27  
4.2.3  Safety Endpoints  ..........................................................................................27  
5. SELECTION OF STUDY POPULATION ......................................................................27
5.1 Subject Population ....................................................................................................27  
5.2 Inclusion Criteria  ......................................................................................................28  
5.3 Exclusion Criteria  .....................................................................................................29  
5.4 Discontinuation of Treatment or Assessments .........................................................31  
5.5 Dietary and Lifestyle Restrictions  ............................................................................33  
6. STUDY TREATMENTS  ...................................................................................................33
6.1 Investigational Products and Controls ......................................................................33  
6.2 Dosing Regimen  .......................................................................................................33  
6.3 Dose Modification ....................................................................................................36  
6.4 Packaging and Labeling  ...........................................................................................36  
6.5 Storage ......................................................................................................................36  
6.6 Assignment to Treatment  .........................................................................................37  
6.6.1  Randomization .............................................................................................37  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 5 - 6.6.2  Blinding ........................................................................................................37  
6.7 Prior and Concomitant Therapy ...............................................................................38  
6.8 Treatment Compliance  .............................................................................................39  
7. VISIT SCHEDULE AND ASSESSMENTS  .....................................................................40  
7.1 Study Procedures  ......................................................................................................40  
7.2 Study Visits and Assessments  ..................................................................................40  
7.2.1  Visit 1 Screening (Day -28 to Day -1) .........................................................40  
7.2.2  Visit 2 – Randomization/Baseline (Day 0)  ..................................................41  
7.2.3  Visit 3 (Week 4), Visit 4 (Week 8), Visit 5 (Week 12), Visit 6 (Week 
16), Visit 7 (Week 20), and Visit 8 (Week  24) ............................................42  
7.2.4  Early Termination Visit ................................................................................43  
7.2.5  Safety Follow -up Visit (Week 25 [+3 days], or 1 Week [+3 days] after 
ETV, unless final dose was taken >7 days prior to Week 24/ETV) .............44  
7.2.6  Unscheduled Visit ........................................................................................44  
7.3 Efficacy Assessments  ...............................................................................................44  
7.3.1  Co-Primary Efficacy Assessments: Psoriasis Area and Severity Index 
and Investigator’s Global Assessment  .........................................................45  
7.3.2  Secondary Efficacy Assessments  .................................................................46  
7.3.2.1  Affected Body Surface Area  ............................................................46  
7.3.2.2  Nail Psoriasis Severity Index ..........................................................46  
7.3.2.3  Psoriasis Scalp Severity Index ........................................................46  
7.3.2.4  Palmoplantar Psoriasis Physician’s Global Assessment (PP PGA)  ................................................................................................47
 
7.3.2.5  Pruritus Numerical Rating System ..................................................47  
7.3.3  Health-related Quality of Life Assessments  .................................................47  
7.3.3.1  Dermatology Life Quality Index......................................................47  
7.3.3.2  12-Item Short Form Survey .............................................................47  
7.3.3.3  Quick Inventory of Depressive Symptomatology-Self Report (16 Items)  ...............................................................................................47
 
7.3.3.4  Work Productivity and Activity Impairment Questionnaire: Psoriasis  ..........................................................................................47
 
7.3.3.5  Health Economics and Outcomes Research ...................................47  
7.4 Assessment of Pharmacokinetics  .............................................................................48  
7.5 Assessment of Safety  ...............................................................................................48  
7.5.1  Adverse Events  .............................................................................................48  
7.5.1.1  Adverse Events Assessments ...........................................................48  
7.5.1.2  Timing  .............................................................................................49  
7.5.1.3  Severity of Adverse Events  ..............................................................50  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 6 - 7.5.1.4  Relationship of an Adverse Event to Study Treatment ....................51  
7.5.1.5  Adverse Event of Special Interest (AESI)  ........................................51  
7.5.2  Serious Adverse Event .................................................................................52  
7.5.3  Safety Laboratory Assessments  ...................................................................53  
7.5.4  Pregnancy Testing  ........................................................................................54  
7.5.5  Vital Signs  ....................................................................................................55  
7.5.6  Physical Examination  ...................................................................................55  
7.5.7  Electrocardiogram  ........................................................................................55  
7.6 Appropriateness of Measurements  ...........................................................................55  
8. STATISTICAL METHODS AND DETERMINATION OF  SAMPLE SIZE 
STATISTICAL AND ANALYTICAL PLANS  ...............................................................55  
8.1 General Considerations for Data Analysis  ...............................................................55  
8.2 Sample Size and Power Considerations ...................................................................56  
8.3 Analysis Populations ................................................................................................56  
8.4 Background and Demographic Characteristics  ........................................................57  
8.5 Study Medication/Visit Compliance  ........................................................................57  
8.6 Prior and Concomitant Therapy ...............................................................................58  
8.7 Analysis of Efficacy  .................................................................................................58  
8.7.1  Co-Primary Efficacy Endpoint(s)  .................................................................58  
8.7.2  Secondary Efficacy Endpoints .....................................................................58  
8.7.3  Handling of Missing Values/Censoring/Discontinuations ...........................59  
8.7.4  Control of Multiplicity  .................................................................................61  
8.8 Analysis of Safety  ....................................................................................................61  
8.8.1  Adverse events  .............................................................................................61  
8.8.2  Laboratory Evaluations ................................................................................61  
8.8.3  Vital Signs  ....................................................................................................61  
8.8.4  Cardiac Assessments  ....................................................................................62  
8.8.5  Other Safety Assessments  ............................................................................62  
8.9 Futility Analysis  .......................................................................................................62  
8.10  Protocol Deviations and Violations ..........................................................................62  
9. CHANGES IN THE PLANNED STUDY  ........................................................................62  
9.1 Protocol Amendments ..............................................................................................62  
9.2 Termination or Suspension of the Study ..................................................................63  
10. DATA HANDLING AND RE CORD KEEPING  ............................................................63  
10.1  Recording of Data  ....................................................................................................63  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 7 - 10.1.1  Source Documents ........................................................................................63  
10.1.2  Case Report Forms  .......................................................................................63  
10.2  Retention of Documents ...........................................................................................64  
11. QUALITY CONTROL AND QUALITY ASSURANCE  ...............................................64  
11.1  Direct Access to Source Documents  ........................................................................64  
11.2  Monitoring Procedures .............................................................................................65  
11.3  Audit and Inspection ................................................................................................65  
12. ETHICS  ...............................................................................................................................65  
12.1  Ethical Conduct of the Study ...................................................................................65  
12.2  Institutional Review Board (IRB) or Independent Ethics Committee (IEC) ...........65  
12.3  Subject Information and Consent  .............................................................................65  
12.4  Disclosure and Confidentiality .................................................................................65  
12.4.1  Confidentiality of Study Documentation .....................................................65  
12.4.2  Privacy of Individual Health Information ....................................................66  
13. EMERGENCY PROCEDURES  .......................................................................................66  
13.1  Emergency Unblinding ............................................................................................66  
13.2  Reporting of Serious Adverse Events and Pregnancies ...........................................66  
13.2.1  Contact Person(s) and Number(s) ................................................................66  
13.2.2  Reporting Procedures ...................................................................................67  
Serious Adverse Events ........................................................................................................67  
14. PUBLICATION POLICY .................................................................................................67  
15. REFERENCE LIST ...........................................................................................................68  
16. APPENDICES  ....................................................................................................................71  
 
LIST OF TABLES  
Table 1-1 Visit Schedule and Assessments .................................................................................18  
Table 6-1 Treatment Schedule - Titration Period (Weeks 1- 5) ...................................................35  
Table 6-2 Titration Regimen  .......................................................................................................35  
Table 6-3 Treatment Schedule: Treatment Period (Weeks 6 -24) ...............................................35  
Table 7-1 Investigator’s Global Assessment (IGA)  ....................................................................46  
Table 7-2 Routine Clinical Laboratory Assessments ..................................................................54  
 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 8 - LIST OF FIGURES  
Figure 4-1 Study Design  ...............................................................................................................26  
  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 9 - LIST OF ABBREVIATION S AND DEFINITION OF TERMS  
Abbreviation  Definition  
AE Adverse event  
ALT  Alanine transaminase  
ANOVA Analysis of variance  
ANCOVA  Analysis of covariance  
Anti-HBc Antibody to hepatitis B virus core antigen  
AST Aspartate transaminase  
ATC Anatomical Therapeutic Chemical Classification System  
BDM Biostatistics and Data Management Group  
BID Twice a day  
BMI Body mass index  
BSA Body surface area  
BUN Blood urea nitrogen  
CRO Contract Research Organization  
CXR Chest x-ray 
DLQI Dermatology Life Quality Index 
DSM-5 Diagnostic and Statistical Manual of Mental Disorders (version 5)  
DMF Dimethyl  fumarate 
ECG Electrocardiogram  
eCOA Electronic Clinical Outcome Assessments  
eCRF Electronic Case Report Form 
EOS End of study 
ER Extended release  
ETV Early termination visit  
EU European Union  
FAE Fumaric acid ester  
FAS Full analysis set  
FDA Food and Drug Administration 
GCP Good Clinical Practice  
GGT Gamma glutamyl transferase 
GI Gastrointestinal  
GMP Good Manufacturing Practice  
HBc Hepatitis B virus core antigen  
HbsAg Surface antigen of the hepatitis B virus 
HCP Healthcare professional  
HCV Hepatitis C virus  
HDL High density lipoprotein  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 10 - Abbreviation  Definition  
HEOR Health Economics and Outcomes Research  
HIV Human immunodeficiency virus  
hsCRP High-sensitivity C reactive protein  
ICF Informed consent form  
ICH International Conference o n Harmonisation 
IEC Independent Ethics Committee 
IP Investigational product  
IGA Investigator’s Global Assessment  
IRB Institutional Review Board  
IL2 InfoLink2  
IXRS Interactive voice and web response system  
LDH Lactate dehydrogenase  
LDL Low density lipoprotein 
LLN Lower limit of normal 
LOCF Last observation carried forward  
MCH Mean corpuscular hemoglobin  
MCHC Mean corpuscular hemoglobin concentration  
MCMC Markov Chain Monte Carlo method  
MCV Mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
MEF Monoethyl  fumarate 
MI Multiple imputation  
MMF Monomethyl fumarate  
MMRM Mixed model for repeated measures  
mNRI Modified non -responder imputation  
MTX Methotrexate  
NAPSI Nail Psoriasis Severity Index  
NRS Numeric rating scale  
OC Observed -cases 
OTC Over-the-counter 
PASI Psoriasis Area and Severity Index   
PASI-50 At least 50% reduction in PASI score  
PASI-75 At least 75% reduction in PASI score  
PD Pharmacodynamic(s)   
PDS Protocol deviation specification  
PGA Physician’s Global Assessment  
PML Progressive multifocal leukoencephalopathy 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 11 - Abbreviation  Definition  
PP Per protocol  
PP PGA Palmoplantar Psoriasis Physician’s Global Assessment  
PSSI Psoriasis Scalp Score Index  
PT Preferred Term  
PUVA Psoralen and ultraviolet A 
QD Once daily 
QIDS-SR16 Quick Inventory of Depressive Symptomatology-Self Report (16 Items) 
QoL Quality of Life  
RBC Red blood cell  
SAE Serious adverse event  
SAP Statistical analysis plan  
SD Standard deviation 
SF-12 12-item Short Form Survey 
SOC System Organ Class 
sPGA Static physician’s global assessment  
SUSAR Suspected unexpected serious adverse reaction  
TB Tuberculosis  
TEAE Treatment -emergent adverse event  
ULN Upper limit of normal 
UPT Urine pregnancy test  
US  United States  
UV Ultraviolet  
VAS Visual analog scale  
WBC White blood cell  
WNL Within normal limits  
WPAI:PSO Work Productivity and Activity Impairment Questionnaire: Psoriasis  
 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 12 - 1. SYNOPSIS  
Study Title: A Randomized, Double -Blind, Placebo -Controlled, Multicenter, 24 -Week 
Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fum arate) 
Extended Release Tablets in Subjects with Moderate- to-Severe Plaque 
Psoriasis 
Protocol Number:  PPC-06-CD-004 
Sponsor:  Dr. Reddy’s Laboratories, SA  
Development Phase:  2 
Study Objectives:  Co-primary objectiv es: 
1. To demonstrate the efficacy of PPC-06 with respect to Psoriasis Area and 
Severity Index (PASI) for the treatment of moderate-to-severe plaque 
psoriasis, as compared to placebo  at 24 weeks 
2. To demonstrate the efficacy of PPC-06 with respect to Investigator’s  
Global Assessment ( IGA) at 24 weeks 
Secondary objectives : 
1. To assess the efficacy of PPC-06 as it relates to psoriasis -related 
symptoms and health -related quality of life (QoL) measures  
2. To assess the safety and tolerability of PPC-06 in subjects with moderate -
to-severe plaque psoriasis  
3. To evaluate the pharmacodynamics (PD) of PPC-06 through 
immunological analysis of peripheral blood samples.  
Study Design:  This is a randomized, double -blind, placebo- controlled, multicenter study  
designed to assess the safety and efficacy of PPC-06 (tepilamide fumarate) 
extended release [ ER] tablets in subjects with moderate -to-severe plaque 
psoriasis. Study subjects will be enrolled at approxima tely 75 sites in the 
United States (US). The study will be comprised of 4 study periods: 1) 
Screening Period, 2) Double -Blind Titration Period, 3)  Double-Blind 
Treatment Period, and 4) Post -treatment Follow -Up Period.  
Following completion of the pre -randomization S creening Period  (up to 4 
weeks), approximately 400 eligible subjects will be randomly assigned in a 
1:1:1:1 ratio to one of the 4  arms (PPC-06 400 mg QD, PPC-06 400 mg BID, 
PPC-06 600 mg BID, or placebo BID)  and the subjects will enter the 5-week 
Double-Blind Titration Period . At Visit 3 (Week 4), the subjects will continue 
1 more week of titration dose (Week 5 of blister wallets) and will also be given 
a kit of bottles which will allow dosing until Visit 4  (Week 8) . 
Subjects will receive d ouble-blind treatment from Week 6 through Week 24. 
Subjects will return to the clinic every 4  weeks (±3  days) thereafter , until 
Week 24, for drug accountability and to undergo safety and efficacy 
evaluations .  Subjects will return at Week 25 for an End of Study (EOS) Safety 
Follow-Up Visit. There are 9 expected visits  total per subject.  
Blood samples for pharmacodynamics ( PD) assessments will be col lected at 
Baseline and at Weeks 4, 8, 12, 16, 20, and 24. PD assessments will be 
conducted for all subjects, with the intent of evaluating psoriasis -associated 
inflammatory markers . Details of PD assessment will be provided in a separate 
protocol. 
The Early Termination Visit (ETV)  will be scheduled  if the study drug is 
permanently discontinued for any reason (for example: due to meeting the 
protocol-mandated safety monitoring criteria or unresolved gastrointestinal 
[GI]-related intolerability).  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 13 - The EOS Saf ety Follow -up Period will consist of 1 visit 1 -week (± 3 days) 
following  the Week 24 Visit or the ETV . In the event that th e Week 24 Visit or 
the ETV occurs > 1 week following the last dose of the study drug, the EOS 
Safety Follow -up Visit may not be required. The ETV and/or EOS Safety 
Follow-Up Visit are not expected to be completed for subjects who withdraw 
full consent or are lost to follow up.  
If necessary, the Investigator may decide to extend the follow -up visits beyond 
1 week to monitor recovery  of safety parameters (e.g., lymphopenia).  
Planned Sample Size:  Approximately 400 subjects (~100 subjects per treatment arm)  
Study Population:  Inclusion  criteria: Subjects must meet all of the following criteria to be 
eligible for participation in the study: 
1. Generally healthy males or non -pregnant females age ≥18 years at the 
time of screening (or who have reached the state minimum legal age of 
consent). 
2. Stable, moderate- to-severe plaque psoriasis diagnosed for at least 
6 months prior to randomization (no morphology changes or significant 
flares of disease activity in the last 6  months in the opinion of the 
investigator  or as reported by the subject ). 
3. Severity of disease meeting all 3 of the following criteria prior to 
randomization (at the Baseline [Day  0] visit): 
a. PASI score of ≥12 
b. Total body surface area ( BSA) affected by plaque psoriasis of ≥10% 
c. IGA score of >3 
4. Must be a candidate for phototherapy and/or systemic therapy for psoriasis.  
5. Ability to independently travel to study center and to comply with  all 
study medication and procedures or identification of a caregiver committed to assuring compliance with those study related activities.  
6. Able to understand and have voluntarily signed an informed consent form (ICF) prior to undergoing any study- specific procedures.  
7. Women of child -bearing potential must have had a negative serum 
pregnancy test at the Screening Visit and a negative urine pregnancy test  
(UPT) at Baseline prior to randomization.  
8. Heterosexual f emale subjects of childbearing potential must ag ree to use 
contraception during the study which can include abstinence with an adequate secondary option should the subject become sexually active. All women of childbearing potential must complete a urine pregnancy test  at 
the baseline visit and the test must be negative to be eligible for enrollment. (Test must have a sensitivity of at least 25  mIU/mL for human 
chorionic gonadotropin).  A female is considered of childbearing potential 
unless she is a) postmenopausal for a t least 12 months prior to study 
product administration b) without a uterus and/or both ovaries; or has been 
surgically sterile (i.e., tubal ligation) for at least 6 months prior to study 
product administration. Reliable methods of contraception are: a) 
hormonal methods or intrauterine device in use ≥ 90 days prior to study 
product administration or barrier method plus spermicide in use at least 14 
days prior to study product administration or partner has had a vasectomy at least 3 months prior to study pro duct administration or Essure®. 
Exception : Sexually inactive female subjects of childbearing potential are 
not required to practice a reliable method of contraception and may be 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 14 - enrolled at the investigator’s discretion provided that they are counseled to 
remain sexually inactive for the duration of the study and understand the 
possible risks involved in getting pregnant during the study.  An abstinent 
heterosexual female must agree that if she becomes sexually active during 
the study she will use an acceptable form of contraception  
9. Willing to avoid excessive sun exposure/tanning during the study.  
Note: If a subject does not meet the inclusion criteria in terms of PASI, 
total BSA, and /or IGA at Screening, but in the opinion of the Investigator, 
the subject could meet the inclusion criteria related to PASI, total BSA, 
and IGA at the Baseline Visit, the subject can be scheduled for the 
Baseline Visit where these eligibility criteria as well as all other inclusion/exclusion criteria must be met before the subject can be 
randomized into the study.  
 
Exclusion Criteria:  Any of the following will be regarded as a reason for 
exclusion from the trial:  
1. Subjects with non -plaque psoriasis (ie, predominantly inverse , 
erythrodermic, predominantly guttate, or pustular psoriasis). 
2. Subjects with drug -induced psoriasis or subjects with drug-exacerbated 
psoriasis that has not resolved  within 4 weeks prior to screening.  
3. Subjects who have received systemic non -biologic psoriasis therapy or 
phototherapy (including either oral and topical psoralen and ultraviolet A  
(PUVA) light therapy, ultraviolet B, or self -treatment with tanning beds or 
therapeutic sunbathing) within 4  weeks prior to the Baseline Visit.  
 Subjects who had topical psoriasis treatment within the previous 2  weeks 
prior to the Baseline Visit.  
 Exceptions: Mild/least potent topical steroids will be permitted for use 
limited to the face, axilla, and/or genitalia.  Medicated shampoos 
containing the active ingredients zinc pyrithione, salicylic acid, selenium 
sulfide, or ketoconazole will be permitted for use in the shower on the 
scalp only . 
4. Subjects with history of concurrent or recent use of any biologic agent 
within the following washout periods prior to baseline visit:  
• Etanercept – 35 days 
• Infliximab, adalimumab - 12 weeks  
• Ustekinumab – 24 weeks  
• Any other biologic agent <5 half -lives prior to the Baseline Visit  
 Note 1: Screening visit can be extended on case -by-case basis (but no 
more than additional 4 weeks) to complete the wash out.  
 Note 2: A maximum of 30% of subjects with prior biologic use (ie, 
subjects who received systemic biologic drugs in the past) will be enrolled, but they must be washed out prior to randomization.  
5. Subjects with prior exposure to natalizumab, rituximab , or belilumab in 
the past 1 year prior to screening visit . 
6. Subjects with history of use of any investigational drug within 28  days 
prior to randomization, or 5 pharmacokinetic/ pharmacodynamic half -lives 
(whichever is longer) . 
7. Subjects wh o have failed on 3  or more systemic therapies . 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 15 - 8. Subjects who cannot avoid excessive sun exposure or use of tanning 
booths for at least 4  weeks prior to the Baseline Visit and during the day  
for the entire duration of the study . 
9. Subjects with unstable or significant illness, including the presence of 
laboratory abnormalities  or electrocardiogram ( ECG) abnormalities,  at 
screening that, in the opinion of the Investigator, would place the subjec t 
at unacceptable risk if he/she were to participate in the study (eg, 
clinically significant abnormality on ECG , any other auto -immune 
conditions where subject is on immunosuppressive agents ).  
10. Subjects with sarcoidosis, active tuberculosis, or incomplete ly treated 
tuberculosis ( TB), or any other serious systemic infection.  
11. Any skin condition (eg, eczema) that would confound the ability to interpret data from the study . 
12. Subjects whose BMI is >39 . 
13. Subjects with a present or past history of any major neurological 
conditions such as stroke, transient ischemic attack , seizures, cranial nerve 
palsies, major head trauma, brain tumor, demyelinating disorders . 
14. Subjects with a current history of any medical condition associated with significant  gastrointestinal ( GI) events such as nausea, vomiting, 
constipation, abdominal pain, or diarrhea, which in the opinion of the investigator would affect the tolerability of the drug . 
15. Subjects with  severe gastritis, duodenal ulcer, severe symptomatic lactose 
intolerance, irritab le bowel syndrome, present or a past history of 
inflammatory bowel disease  or severe dysphagia.  
16. Subjects with a persistent history  (more than 3 consecutive months) of 
lymphopenia (below the lower limit of normal [ LLN]) in the last 2  years. 
17. Subjects who had  prior treatment with dimethyl fumarate (Fumaderm
® or 
Tecfidera®) or any other fumaric acid ester (FAE) containing products . 
18. Subjects who at S creening and/or randomization have uncontrolled high 
blood pressure values, which, in the opinion of the Investiga tor, may 
increase the risk of cardiovascular events . 
19. Subjects who at Screening have creatinine clearance <60 mL/min. 
20. Subjects who , according to the Reference Laboratory Manual, at 
Screening have:  
a. White blood cells (WBC) < 3000/mm³  
b. Neutrophils/granulocytes less than the LLN 
c. Platelets <110,000 / mm³ 
d. Lymphocytes < 1000/mm³  
e. Serum creatinine >1.5× the upper limit of normal ( ULN) 
f. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2×ULN 
g. Significant proteinuria  measured as 3+ or above in urine dipstick in 
two samples taken on two different days  
h. Non-fasted blood glucose > 200mg/d L 
Note: Laboratory tests that cross these thresholds can be repeated once if 
the Investigator has a clinical reason to believe that a result may be 
erroneous in which case the laboratory result should be discussed and agreed with the Medical Monitor before repeating it. The repeat value can be accepted if it meets protocol criterion.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 16 - Subjects who have chronically abnormal laboratory values  beyond any of 
the above exclusionary thresholds are excluded even if they are deemed 
clinically normal. 
21. Subjects who had positive results at Screening for hepatitis B (HBsAg and anti-HBc), hepatitis C, or human immunodeficiency virus (HIV) . 
22. Subjects who have a known immunodeficiency, receive immune modulatory/immune suppressant therapy, or are immunocompromised .  
23. Subjects with malignancy (except for adequately treated basal cell 
carcinoma, squamous cell carcinoma and carcinoma in situ of the cervix)  
or subjects with history of malignancy, with evidence of recurrence within 
the previous 5 years. 
24. Subjects with a history of drug or alcohol use disorder based on the Diagnostic and Statistical Manual of Mental Disorders (DSM -5) criteria 
(within the 6  months prio r to screening) as reported by the subject or 
known to the Investigator . 
25. Subjects with cognitive deficit or psychiatric syndrome of any etiology that may influence compliance with study procedures or study outcome.  
26. Subjects with a history of allergy to an y component of the study drug. 
27. Women who are lactating or breastfeeding . 
28. Investigator site personnel directly affiliated with this study and/or their immediate families . 
29. Sponsor employees or its designee or employees of third- party 
organizations involved in the study . 
30. Prisoners or subjects who are involuntarily incarcerated . 
Investigational Product(s): PPC-06 (tepilamide fumarate ) Extended Release Tablets  for oral 
administration: 400 mg QD regimen, 400  mg BID regimen, 600  mg BID 
regimen, or Placebo BID regimen. A 5-week Double-Blind Titration Period 
will be followed b y a 19-week Double-Blind Treatment P eriod. 
Reference Product(s):  Not applicable  
Control Product(s):  Placebo tablets for oral administration to match PPC-06 Extended Release 
Tablets 
Efficacy Evaluation 
Criteria: Efficacy assessments include the PASI, the affected BSA,  and the IGA.  
Health-related QoL assessments include the Quick Inventory of Depressive 
Symptomatology -Self Report (16 Items) (QIDS -SR16), the Dermatological  
Life Quality Index ( DLQI), the 12-item Short Form Survey (SF -12), the Work 
Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI :PSO), 
and evaluation of Health Economics and Outcomes Research (HEOR).  
Other assessments  (for subjects with psoriasis in the relevant areas) include the 
Nail Psoriasis Severity Index (NAPSI), the Psoriasis Scalp Score Index (PSSI) , 
the Palmoplantar Psoriasis Physician’s Global Assessment ( PP PGA) score, 
and the Pruritus Numerical Rating scale (NRS). PD assessments would include 
immunological analysis of peripheral blood samples . Details of PD assessment 
will be provided in a separate protocol.  
Pharmacokinetics Evaluation Criteria:  Not applicable  
Safety Evaluation Criteria:  Adverse event (AE) incidence and severity, laboratory test results 
(hematology, clinical chemistry, urinalysis), vital signs (systolic and diastolic blood pressure, heart rate, respiratory rate), physical examination , ECGs, and 
pregnancy testing.
 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 17 - Efficacy Endpoints  The co-primary efficacy endpoint s will be the proportion of subjects who 
achieve a reduction of 75% or greater from Baseline PASI (PASI-75) at the 
end of Week  24 and the proportion of subjects who achieved a n IGA score of 
clear or almost clear ( IGA 0, 1) at the end of Week  24. 
Secondary efficacy endpoints  include the following:  
• Change from Baseline and percent change from Baseline in total PASI 
score at each visit in the Double -Blind Treatment  Period 
• The proportion of subjects who achieve PASI -50 and PASI -75 at each 
visit in the Double -Blind Treatment  Period 
• The proportion of subjects who achieved a n IGA score of clear or almost 
clear at each visit in the Double -Blind Treatment Period  
• The change from Baseline and percent change from Baseline in percent of affected BSA at each visit in the Double -Blind Treatment Period  
• Mean change in the NAPSI  of the target fingernail  (score range 0 -8) from 
Baseline at Weeks  12, 16 and 24 in the target fingernail with the most 
severe abnormalities  for those who present with lesions in nails at baseline  
• Mean change in the PSSI score from Baseline at each visit in the  Double -
Blind Treatment Period  for those that present with lesions on scalp at 
baseline 
• Mean change in the Palm oplantar Psoriasis Physician’s Global Assessment 
(PP PGA) score from Baseline at each visit in the  Double -Blind 
Treatment Period for those that present with lesions on the palms/soles at baseline 
• The change from Baseline and percent change from Baseline in pruritus NRS score at each visit in the Double -Blind Treatment Period  
• Time to achieving a PASI -75 response, defined as time in days from 
baseline to first achieving a reduction of 75% o r greater from Baseline in 
PASI 
• Time to achieving an IGA score of clear or almost clear, defined as time in days from baseline to first achieving a n IGA score of 0 or 1 
 
Health-related QoL assessments include:  
• QIDS-SR16 total score  
• DLQI total score  
• SF-12 total score  
• WPAI:PSO score  
• HEOR evaluation  
Safety Endpoints : 
Safety will be assessed through the monitoring of AEs, laboratory test results, 
vital signs, physical examinations,  pregnancy testing and ECGs .  
Study Sites:  Approximately 75 study sites in  the US 
Planned Dates of Study:  November 2017 to January 2019  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 18 - Table 1-1 Visit Schedule and Assessments  
Evaluation  Screening 
Period1 Double -Blind 
Titration Period  
(5 weeks)  Double -Blind Treatment Period  ETV  and EOS Safety  
Follow -up Period2 Un- 
scheduled  
Visit3 
Weeks  
-4 to 0 Baseline 
visit Week 
4 Week 
8 Week 
12 Week 
16 Week 
20 Week 
24 Early 
Termin -
ation 
Visit  Week 2 5 
(1 Week 
After Week 
24/ETV )  
Study Day  Day -28 to 
Day -1 Day 0  Day 
28  
(± 3 
days)  Day 56  
(± 3 
days)  Day 
84  
(± 3 
days)  Day 
112  
(± 3 
days)  Day 
140  
(± 3 
days)  Day 
168  
(± 3 
days)  - 175 (+3 
days)   
Visit Number  1 2 3 4 5 6 7 8 ETV  9 UNS  
Informed Consent  X           
Inclusion/Exclusion Criteria  X4 X5          
Demographics  X           
Psoriasis Medical 
History/Prior  Psoriasis 
Therapies  X X          
Other Medical History/Prior 
Meds X X          
Concomitant Medications  X X X X X X X X X X X 
Washout of Prohib ited Meds  X           
Confirm washout of 
prohibited  meds  X          
Study Process / Study Drug Dispensation  
Randomization   X          
Study Drug Dispensing   X6 X X X X X     
Drug Accountability/  
Compliance    X X X X X X X   
Collect Baseline stool 
consistency using Bristol 
Stool Chart   X          
Dispense Educational 
Materials for AE 
Management   X          
Safety Assessments  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 19 - Evaluation  Screening 
Period1 Double -Blind 
Titration Period  
(5 weeks)  Double -Blind Treatment Period  ETV  and EOS Safety  
Follow -up Period2 Un- 
scheduled  
Visit3 
Weeks  
-4 to 0 Baseline 
visit Week 
4 Week 
8 Week 
12 Week 
16 Week 
20 Week 
24 Early 
Termin -
ation 
Visit  Week 2 5 
(1 Week 
After Week 
24/ETV )  
Study Day  Day -28 to 
Day -1 Day 0  Day 
28  
(± 3 
days)  Day 56  
(± 3 
days)  Day 
84  
(± 3 
days)  Day 
112  
(± 3 
days)  Day 
140  
(± 3 
days)  Day 
168  
(± 3 
days)  - 175 (+3 
days)   
Visit Number  1 2 3 4 5 6 7 8 ETV  9 UNS  
Complete Physical 
Examination X           
Partial Physical Exam ination  X X X X X X X X X X 
Height X           
Weight X  X X X X X X X  X 
Waist Circumference  X       X X   
Vital Signs  X X X X X X X X X X X 
12-lead ECGs  X X X X X X X X X X  
Serum Pregnancy Test X           
Urine Pregnancy Test   X X X X X X X X X  
Laboratory Assessments7 X X X X X X X X X  X 
Blood collection – PD study   X X X X X X X    
Blood collection for 
lymphocyte  subset & Ab 
titer study8  X      X X   
Serology (HIV, HBsAg, Anti-
HBc, HCV)  X           
Adverse Event Assessment  X9 X X X X X X X X X X 
Efficacy Assessments10 
PASI, BSA, IGA X X X X X X X X X X  
PSSI, PP PGA, Pruritus NRS  X X X X X X X X X  
NAPSI   X   X X  X X X  
Health -related Quality of Life Assessments10 
QIDS-SR16, DLQI, SF -12, 
WPAI:PSO, HEOR   X   X X  X X X  
Photography  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 20 - Evaluation  Screening 
Period1 Double -Blind 
Titration Period  
(5 weeks)  Double -Blind Treatment Period  ETV  and EOS Safety  
Follow -up Period2 Un- 
scheduled  
Visit3 
Weeks  
-4 to 0 Baseline 
visit Week 
4 Week 
8 Week 
12 Week 
16 Week 
20 Week 
24 Early 
Termin -
ation 
Visit  Week 2 5 
(1 Week 
After Week 
24/ETV )  
Study Day  Day -28 to 
Day -1 Day 0  Day 
28  
(± 3 
days)  Day 56  
(± 3 
days)  Day 
84  
(± 3 
days)  Day 
112  
(± 3 
days)  Day 
140  
(± 3 
days)  Day 
168  
(± 3 
days)  - 175 (+3 
days)   
Visit Number  1 2 3 4 5 6 7 8 ETV  9 UNS  
Photography ( 4 sites, 
5 subjects/site )  X   X X  X    
1. The Screening Period can only be extended on a case-by -case basis if a longer than 4 weeks’ washout is required; however, the Investigator will need to obtain approval 
from the Medical Monitor  in advance of the extension . 
2. Subjects who permanently discontinue the study drug for any reason or who withdraw from the study prematurely prior to the end of the Double -Blind Treatment Per iod 
should undergo the ETV followed by the EOS Safety Follow -up Period Visit.  In the event that the ETV or Week 24 Visit occurs > 1 week following the last dose of the 
study drug, the EOS Safety Follow -up Visit may not be required.  If necessary, the Investigator may decide to extend the EOS Safety F ollow-up Visits beyond 1 week to 
monitor recovery of safety parameters ( eg, lymphopenia).  
3. Table includes recommended . Unscheduled procedures, whichever are applicable, should be performed at the Investigator’s discretion.  
4. Initial eligibility assessment.  
5. Mandatory confirmatory eligibility assessment.  
6. Study drug will be dispensed as per the titration schedule described in Double-Blind Titration section . 
7. Laboratory assessments include routine laboratory evaluations  (i.e., chemistry, hematology, and urinalysis), and assessment of lipid panel and hsCRP   
8. Blood collection for lymphocyte subset & Ab titer  study can be collected at any study visit if the subject shows signs of  progressive multifocal leukoencephalopathy  
(PML). 
9. SAEs will be collected following the signing of the Informed Consent Form; AEs will be collected following the first dose of study drug.  
10. Electronic device (for example: Electronic Clinical Outcome Assessments [eCOA]) will be used to record the efficacy and the health -related QoL assessments.  The PSSI, 
PP PGA, and NAPSI will be assessed for all subjects at Baseline; if score is 0 at Baseline for any of these assessments, then the respective assessment (s) would not be 
required to be completed at future s tudy visits , At baseline, the NAPSI will be evaluated for the 10 fingernails and the worst affected nail  (maximum score)  will be chosen 
as the target nail. Only the target nail will be evaluated in the subsequent visits.  
Abbreviations: Ab = antibody; Anti-HBc = Hepatitis B virus core antigen; BSA = Body surface area; DLQI = Dermatological Life Quality Index; ECG = Electrocardiog ram; 
EOS = End of Study; ETV  = Early Termination Visit; HBsAg = Hepatitis B virus surface antigen; HCV = Hepatitis C virus; HEOR = Health Economics and Outcomes 
Research; HIV = Human immunodeficiency virus; hsCRP = High -sensitivity C reactive protein; NAPSI = Nail Psoriasis Severity Index; PASI = Psoriasis Area and Severity 
Index;  PD = pharmacodynamics;  PP PGA = Palmoplantar psoriasis physician’s global assessment ; PSSI = Psoriasis Scalp Score Index; QIDS -SR16 = Quick Inventory of 
Depressive Symptomatology -Self Report (16 Items); SF -12 = 12-item Short Form Survey; IGA = Investigator’s Global Assessment; NRS = Numerical rating scale; 
WPAI:PSO = Work Productivity and Activity Impairment Questionnaire: Psoriasis  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 21 - 2. INTRODUCTION 
The investigational product (IP) in this study is PPC-06 (tepilamide  fumarate) extended release 
(ER) tablets, previously known as XP23829, which is a patented, oral product candidate that 
utilizes prodrug technology for efficient absorption into the body. Once absorbed, PPC -06 is 
rapidly converted to monomethyl fumarate (MMF), a fumaric acid ester (FAE) compound that 
has shown immunomodulatory and neuroprotective effects in cell-based systems and various preclinical models of disease. The current trial will examine  the safety and efficacy of PPC-06 in 
the treatment of moderate -to-severe plaque- type psoriasis.  
2.1 Plaque Psoriasis  
Psoriasis is a chronic T -cell–mediated autoimmune disease ( Ghoreschi, 2007) that affects 2% to 
3% of the US population ( Stern, 2004; Kurd, 2009 ) and 0.6% to 6.5% of the European 
population ( Chandran, 2010). As many as an estimated 7.5 million Americans are thought to 
have psoriasis, making it the most common autoimmune disease in the United States ( National 
Psoriasis Foundation). The most common phenotypic form of psoriasis, plaque psoriasis, manifests as raised, well -demarcated, red plaques with silver scales  that may remit spontaneously 
or recur in response to environmental triggers ( Nestle, 2009).  
In addition to the appearance of skin plaques, there is a high degree of physical morbidity associated with psoriasis. Up to 30% of patients develop psoriatic arthritis ( Zanni, 2012 ). 
Individuals with psoriasis appear to be at higher risk for a number of co-morbid conditions including obesity, myocardial infarction, cancer, diabetes mellitus, Crohn’s disease and 
depression ( Krueger, 2001;  Davidovici, 2010; Mehta, 2010). Patients with severe psoriasis, on 
average, die five years younger than patients without psoriasis, an observation that is largely 
attributable to an increased risk of cardiovascular disease ( Prodanovich, 2009). In addition, 
psoriasis can represent both a significant social and financial burden for patients. Individuals suffer from both disfigurement and social stigmatization, with an impact on mental disability 
comparable with that of other major medical illnesses such as heart disease and rheumatoid 
arthritis (Sterry, 2009). Patients with psoriasis, like those with other major medical disorders, 
have a reduced quality of life (QoL) and reduced levels o f employment and income ( Horn, 
2007).  
The currently available psoriasis treatments do not offer a cure. Treatment is aimed at reducing 
the burden of disease and achieving an improvement in its signs and symptoms ( Laws, 2012). 
Topical agents are generally prescribed for mild and some moderate cases, while systemic agents (including biologics), and phototherapy are reserved for moderate and severe cases. Treatment 
decisions are based not only on the severity of the disease, but also on existing comorbidities, 
tolerability, side effects, and patient preferences . Several systemic agents, including methotrexate 
(MTX), cyclosporine, and retinoids are most commonly used ( Laws, 2012). Various factors limit 
favorable long- term outcomes ; in particular , a lack of cons istent efficacy over time and the risk 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 22 - of serious cumulative toxicity . Injectable biologic agents are effective for a substantial number of 
patients, but there is concern regarding long-term safety due to the risk of immunosuppression 
and the potential for development of infections, opportunistic diseases, or malignancy ( Laws, 
2012; Palfreeman, 2013).  
2.2 Fumaric Acid Esters  
Fumaric acid, an unsaturated dicarboxylic acid, is an intermediate in the citric acid cycle (Krebs 
cycle) and is present naturally in all  cells capable of aerobic respiration. Orally administered 
fumaric acid is poorly absorbed and is believed to pass through the body without causing significant systemic effects . To overcome the absorption limitations of fumaric acid, simple alkyl 
esters of fumaric acid (FAEs), including dimethyl  fumarate (DMF) and monoethyl  fumarate 
(MEF) were synthesized and evaluated for the treatment of psoriasis in the late 1950s 
(Schweckendiek, 1959).  
Fumaderm
®, an enteric -coated oral formulation of DMF together with the calcium, magnesium 
and zinc salts of MEF ( Fumaderm Summ ary of Product Characteristics [ SPC] 2009) and 
Tecfidera®, an oral formulation of DMF without the additional MEF salts, were the first and 
second commercial products in the FAE class. Fumaderm was first approved in Germany for the 
treatment of severe psoriasis and for moderate- to-severe psoriasis vulgaris. Tecfidera is approved 
in the US for the treatment of relapsing forms of multiple sclerosis. In clinical trials, both 
Fumaderm ( Ormerod, 2004; Nast, 2006;  Altmeyer, 1994, 1996; Mrowietz, 1997, 1999) and 
Tecfidera (Langner 2005, Mrowietz 2005) demonstrated clinical efficacy in subjects with 
psoriasis. Both products are associated with flushing and gastrointestinal (GI) side effects such as nausea and diarrhea, and abdominal pain is also a common effect of Tecfidera . Reversible 
leucopenia, lymphopenia, and transient eosinophilia are frequently observed with Fumaderm; however, Tecfidera has been shown to reduce blood lymphocyte counts in multiple sc lerosis 
patients during the first year of treatment (Tecfidera Prescribing Information, 2017).  
2.3 Investigational Product 
PPC-06 (tepilamide fumarate), previously known as XP23829, is a novel ester prodrug of MMF 
and a member of the FAE class of drugs . In a similar manner to DMF, tepilamide fuma rate 
generates MMF during absorption and intact PPC -06 prodrug does not reach systemic 
circulation . MMF is the presumed active metabolite of both Tecfidera and Fumaderm. Following 
oral administration, PPC-06 is rapidly absorbed and hydrolyzed to release MMF and promoiety 
by non-specific esterases in intestinal tissues . Systemic exposure to intact PPC-06 after oral 
dosing in humans is negligible and the pharmacologic activity of PPC -06 is attributed to the 
release of the active moiety, MMF . PPC-06 is absorbed throughout the GI tract, and therefore 
has been successfully incorporated into an extended- release (ER) formulation, in contrast to 
existing immediate -release formulations of currently available FAEs ( Fumaderm S PC, 2009; 
Tecfidera Prescribing Information , 2017). 
Dr. Reddy’s Laboratories , SA 
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
- 23 - Administration  of PPC-06 reduced lymphocytes and increased eosinophils in healthy subjects. 
After 7 days of dosing PPC-06 (Day 8), the mean absolute reduction in blood lymphocytes from 
baseline ranged from -0.84 to -1.16 × 109 /L (compared to reductions of -0.32 for DMF and -0.23 
for placebo). Lymphocytes remained within normal limits (WNL) in the majority of subjects and 
did not drop below 0.5 × 109 /L (or below grade 2) in any subject evaluated. These lymphocyte 
reductions were reversible, restoring to near baseline levels at the follow-up visit. Blood 
eosinophils were increased within normal limits by a mean of 0.12 to 0.20 × 109/L from baseline 
for PPC-06, 0.01 for DMF, and 0.02 for placebo (se e Investigator’s Brochure for PPC-06 
[tepila
mide fumarate] Extended Release Tablets).  
In 3 Phase 1 studies in hea lthy volunteers conducted to date, P PC-06 was generally well-
tolerated and safe. The most common adverse events (AEs) of flushing and GI symptoms 
(nausea, diarrhea and abdominal pain) were consistent with AEs known to be associated with 
FAEs (see Investigator’s Brochure for PPC-0 6 [tepilamide f umarate] Extended  Release T ablets). 
A Phase 2 study (XP-H- 093) examined the safety and efficacy of PPC-06 400 mg QD, 800 mg 
Q
D, 400 mg twice daily (BID), and placebo in a ppr oximately 200 patients with moderate-to-
severe plaque- type psoriasis. Efficacy assessments included the Psoriasis Area and Severity 
Index (PASI), the affected body surface area (BSA), the static Physician’s Global Assessment 
(sPGA), the Dermatology Life Quality Index (DLQI), and the Pruritus Visual Analog Scale 
(VAS). The PPC-06 800 mg QD and PPC-06 400 mg BID formulations demonstrated 
statistically significant  efficacy as defined by the primary efficacy endpoint (percent change from 
Baseline in total PASI score at Week 12), but did not achieve statistical significanc e for key 
secondary endpoints such as PASI-75 (at least 75% reduction in PASI score) and  sPGA responder 
analyses, for which the study was not powered (see Investigator’s Brochure for
 PPC- 06 
[tepilamide f umarate] Extended Release Tablets). The safety profile of XP2829 was consistent 
with the known safety profile of the FAE medication class, particularly GI-related AEs, but some 
tolerability results, although limited by the short duration of the study, were potentially favorable 
in terms of lymphopenia and flushing (see Investigator’s Brochur
e for PPC-  06 [tepilamide 
fumarate] Extended Release T ablets). 
2.4 Rati
onale of the Study  
There remains a strong unmet need for safe and convenient oral therapies that can be used long-
term for the treatment of moderate -to-severe chronic plaque-type psoriasis. Despite the 
availability of  other therapeutic options, the long- term management of psorias is is complicated 
by a number of serious treatment -related limitations.  Various factors limit favorable long- term 
outcomes, in particular, their lack of consistent efficacy over time and the risk of serious cumulative toxicity.  
Based on Phase 1 studies in healthy volunteers (studies XP-H-058, XP-H-059, XP-H-076, and 
XP-H-116) and a Phase 2 study in moderate- to-severe plaque psoriasis patients (XP -H-093), 
Dr. Reddy’s Laboratories , SA 
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
- 24 - PPC-06 (tepilamide fumarate)  ER tablets can provide not only a more sustained MMF exposure, 
but also may have the potential to provide an improved tolerability profile compared to other 
FAE prodrugs (ie, lower incidence and intensity of flushing and GI symptoms). In addition to a 
potential improvement in tolerability, the sustained exposure of MMF provided by PPC -06 ER 
tablets may also offer the convenience of a once- daily oral treatment in psoriasis. The current 
trial is aimed at investigating the safety and eff icacy of PPC-06 in the treatment of moderate -to-
severe plaque- type psoriasis.  
3. TRIAL  OBJECTIVES  AND PURPOSE
The co-primary objective s of this study are as follows: 
1. To demonstrate the efficacy of PPC-06 with respect to PAS I for the treatment of
moderate- to-severe plaque psoriasis, as compared with placebo at 24 weeks
2. To demonstrate the efficacy of PPC -06 with respect to IGA at 24 weeks
Secondary objectives are as follows : 
1.To assess the efficacy of PPC-06 as it relates to psoriasis -related symptoms and health -
related QoL measures
2.To assess the safety and tolerability of PPC-06 in subjects with mod erate-to-severe
plaque psoriasis
3.To evaluate the pharmacodynamics ( PD) of PPC-06 through immunological analysis of
peripheral blood samples.
4. STUDY DESIGN
4.1 Overall Study Design  
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to 
assess the safety and efficacy of PPC-06 in subjects with moderate -to-severe plaque psoriasis. 
Study subje cts will be enrolled at approximately  75 sites in the United States (US).  
Approximately 400 subjects who meet the study entry criteria will be randomly assigned in a 
1:1:1:1 ratio to 1 of the 4 treatment arms:  
1.PPC-06 400 mg once daily (QD)
2.PPC-06 400 mg BID
3.PPC-06 600 mg BID
4. Placebo BID
The maximum study duration for each subject will be approximately 29 weeks. The study will 
include an up- to-4-week screening phase (which can be extended if necessary on a case- by-case 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 25 - basis for washout of prohibited prior medication), a 24-week treatment phase (that includes a 
5-week titration phase and a 1 9-week treatment period at the maintenance dose), and a 1- visit, 
1-week End-of-Study (EOS) Safety Follow -up Period. If necessary, the Investigator may decide 
to extend the EOS beyond 1 week to monitor recovery of safety parameters (eg, lymphopenia).  
Blood samples for PD assessments will be collected at baseline and at Weeks 4, 8, 12, 16, 20, 
and 24. PD assessments will be conducted in all subjects, with the intent of evaluating psori asis-
associated inflammatory markers . Details of PD assessment will be provided in a separate 
protocol.  
 Subjects who discontinue study drug for more than 2 consecutive weeks due to tolerability issues 
or for any other reason at any point during the study will not be allowed to resume treatment with 
study drug and will be scheduled for the early termination visit (ETV). For those subjects where 
the ETV occurs 1 week or more post the last study drug dose, the safety follow up visit is not required. Subjects who discontinue from the study for any other reason at any time point will 
directly continue to the ETV and then enter the EOS Safety Follow-up period (if required).  
After having provided written informed consent, the subject will undergo screening procedures. 
At the end of the screening period, eligible subjects will be randomly assigned to one of the 
study treatment groups on Day 0 (Baseline) . During the Titration/Treatment Periods, subjects 
will return to the study site according to the study sche dule for efficacy assessments, review of 
study drug compliance, and assessment of concomitant medications, vital signs, AEs, and other 
safety parameters . At specified visits, subjects will be asked to complete questionnaires for Qo L 
assessments. The study design is illustrated  in Figure 4-1. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 26 - Figure 4-1 Study Design  
 
4.2 Study Endpoints  
4.2.1 Efficacy Endpoints 
The co-primary efficacy endpoint s are as follows:  
• The proportion of subjects who achieve a reduction of 75% or greater from Baseline in 
the Psoriasis Area and Severity Index  (PASI-75) at the end of Week  24 
• The proportion of subjects who achieve an IGA score of clear or almost clear ( IGA score 
0 or 1) at the end of Week 24 
Secondary efficacy endpoints include the following: 
• Change from Baseline and percent change from Baseline in total PASI score at each visit 
in the Double- Blind Treatment Period  
• The proportion of subjects who achieve PASI-50 and PASI-75 at each visit in the Double-Blind Treatment Period  
• The proportion of subjects who achieve an IGA score of clear or almost clear at each visit 
in the Double- Blind Treatment Period  
• The change from Baseline and percent change from Baseline in percent of affected BSA at each visit  in the Double- Blind Treatment Period  

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 27 - • Mean change in the NAPSI (score range 0 -8) from Baseline at Weeks 12, 16 and 24 in 
the target fingernail with the most severe abnormalities for those  who present with 
lesions in finger nails at baseline  
• Mean change in the PSSI score from Baseline at each visit in the  Double-Blind 
Treatment Period for those that present with lesions on scalp at baseline  
• Mean change in the Palm oplantar Psoriasis Physicia n’s Global Assessment  (PP PGA) 
score from Baseline at each visit in the  Double-Blind Treatment Period for those that present with lesions on the palms/soles at baseline  
• The change from Baseline and percent change from Baseline in pruritus NRS score at 
each visit in the Double- Blind Treatment Period  
• Time to achieving a PASI -75 response, defined as time in days from baseline to first 
achieving a reduction of 75% or greater from Baseline in PASI   
• Time to achieving an IGA score of clear or almost clear, defined as time in days from baseline to first a chieving an IGA score of 0 or 1 
 
4.2.2 Health Outcome/Quality of Life Endpoints  
Change from Baseline in the following health outcome/QoL assessments at Weeks 12, 16, and 
24: 
• Quick Inventory of Depressive Symptomatology-S elf Report (16 Items) ( QIDS-SR16) 
total score  
• DLQI total score  
• SF-12 total score 
• Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO ) score 
• Health Economics and Outcome Research (HEOR) evaluation  (see Section 7.3.3.5) 
4.2.3 Safety Endpoints  
Safety will be assessed through the monitoring of AEs, laboratory test results, vital signs, 
physical examinations,  pregnancy testing, and 12-lead ECGs.  
5. SELECTION OF STUDY POPULATION 
5.1 Subject Population 
Approximately 400 subjects (~100 subjects per treatment arm) w ill be enrolled in the study. A 
rationale for the choice of sample size is provided in Section  8.2 of this protocol. 
Each potential subject will sign and date the most recently IRB approved  informed consent 
document before any study- specified procedures are performed.   
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 28 - 5.2 Inclusion Criteria  
Subjects must meet all the following criteria to be eligible for participation in the study:  
1. Generally healthy males or non -pregnant females age ≥18 years at the time of screening 
(or who have reached the stat e minimum legal age of consent).  
2. Stable, moderate- to-severe plaque psoriasis diagnosed for at least 6 months prior to 
randomization (no morphology changes or significant flares of disease activity in the last 
6 months in the opinion of the investigator or as reported by the subject). 
3. Severity of disease meeting all 3 of the following criteria prior to randomization (at the Baseline [ Day 0] visit): 
a. PASI score of ≥12 
b. Total body surface area (BSA) affected by plaque psoriasis of ≥10% 
c. IGA score of >3 
4. Must be a candidate for phototherapy and/or systemic therapy for psoriasis.  
5. Ability to independently travel to study center and to comply with all study medication and procedures or identification of a caregiver committed to assuring compliance with those study related activities.  
6. Able to understand and have voluntarily signed an informed consent form (ICF) prior to undergoing any study- specific procedures.  
7. Women of child-bearing potential must have had a negative serum pregnancy test at the Screening Vis it and a negative urine pregnancy test (UPT) at Baseline prior to 
randomization. 
8. Heterosexual f emale subjects of childbearing potential must agree to use contraception 
during the study which can include abstinence with an adequate secondary option should the subject become sexually active. All women of childbearing potential must complete a urine pregnancy test at the baseline visit and the test must be negative to be eligible for 
enrollment. (T est must have a sensitivity of at least 25  mIU/mL for human chorionic 
gonadotropin). A female is considered of childbearing potential unless she is a) postmenopausal for at least 12 months prior to study product administration; b) without a uterus and/or both ovaries; or has been surgically sterile (i.e., tubal ligation) for at least 6 months prior to study product administration. Reliable methods of contracept ion are: a) 
hormonal methods or intrauterine device in use ≥ 90 days prior to study product administration or barrier method plus spermicide in use at least 14 days prior to study product administration or partner has had a vasectomy at least 3 months prio r to study 
product administration or Essure®. Exception: Sexually inactive female subjects of 
childbearing potential are not required to practice a reliable method of contraception and may be enrolled at the investigator’s discretion provided that they are counseled to remain 
sexually inactive for the duration of the study and understand the possible risks involved in getting pregnant during the study.  An abstinent heterosexual female must agree that if 
she becomes sexually active during the study she will use an acceptable form of contraception. 
9. Willing to avoid excessive sun exposure/tanning during the study. 
 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 29 - Note: If a subject does not meet the inclusion criteria in terms of PASI, total BSA, and /or IGA at 
Screening, but in the opinion of the Investigator, the subject could meet the inclusion criteria 
related to PASI, total BSA, and IGA at the Baseline Visit, the subject can be scheduled for the 
Baseline Visit where these eligibility criteria as well as all other inclusion/exclusion criteria must 
be met before the subject can be randomized into the study. 
 
5.3 Exclusion Criteria  
Any of the following will be regarded as a reason for exclusion from the trial: 
1. Subjects with non-plaque psoriasis (ie, predominantly inverse, erythrodermic, 
predominantly guttate, or pustular psoriasis). 
2. Subjects with drug-induced psoriasis or subjects with drug- exacerbated psoriasis that has 
not resolved within 4 weeks prior to screening. 
3. Subjects who have received systemic non -biologic psoriasis therapy or phototherapy 
(including eith er oral and topical psoralen and ultraviolet A ( PUVA) light therapy, 
ultraviolet B, or self -treatment with tanning beds or therapeutic sunbathing) within 
4 weeks prior to the Baseline Visit.  
Subjects who had topical psoriasis treatment within the previous 2 weeks prior to the Baseline Visit.  
Exceptions: Mild/least potent topical steroids will be permitted for use limited to the face, axilla, and/or genitalia.  Medicated shampoos containing the active ingredients zinc 
pyrithione, salicylic acid, selenium sulfide, or ketoconazole will be permitted for use in 
the shower on the scalp only 
4. Subjects with history of concurrent or recent use of any biologic agent within the following washout periods prior to baseline visit: 
• Etanercept – 35 days 
• Infliximab, adalimumab - 12 weeks 
• Ustekinumab – 24 weeks 
• Any other biologic agent <5 half-lives prior to the Baseline Visit  
Note 1: Screening visit can be extended on case- by-case basis (but no more than 
additional 4 weeks) to complete the wash out. 
Note 2: A maximum of 30% of subjects with prior biologic use (ie, subjects who received 
systemic biologic drugs in the past) will be enrolled, but they must be washed out prior to randomization. 
5. Subjects with prior exposure to natalizumab, rituximab, or belilumab in the past 1 year    
prior to screening visit. 
6. Subjects with history of use of any investigational drug within 28 days prior to 
randomization, or 5 pharmacokinetic/ pharmacodynamic half -lives (whichever is longer).  
7. Subjects who have failed to improve on 3 or more systemic therapies.  
8. Subjects who cannot avoid excessive sun exposure or use of tanning booths for at least 
4 weeks prior to the Baseline Visit and during the day for the entire duration of the study. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 30 - 9. Subjects with unstable or significant illness, including the presence of laboratory 
abnormalities or electrocardiogram (ECG) abnormalities, at Screening that, in the opinion 
of the Investigator, would place the subject at unacceptable risk if he/she were to participate in the study (eg, clinicall y significant abnormality on ECG, any other auto-
immune conditions where subject is on immunosuppressive agents).  
10. Subjects with sarcoidosis, active tuberculosis, or incompletely treated tuberculosis (TB), or any other serious systemic infection. 
11. Any skin condition (eg, eczema) that would confound the ability to interpret data from the study. 
12. Subjects whose BMI is >39. 
13. Subjects with a present or past history of any neurological conditions such as stroke, transient ischemic attack,  seizures, cranial nerve palsies, major head trauma, brain tumor, 
demyelinating disorders.  
14. Subjects with a current history of any medical condition associated with significant gastrointestinal (GI) events such as nausea, vomiting, constipation, abdominal pain, or diarrhea, which in the opinion of the investigator would affect the tolerability of the drug. 
15. Subjects with severe gastritis, duodenal ulcer, severe symptomatic lactose intolerance, irritable bowel syndrome, present or a past history of inflammatory bowel disease or severe dysphagia.  
16. Subjects with a persistent history (more than 3 consecutive months) of lymphopenia (below the lower limit of normal [LLN]) in the last 2  years. 
17. Subjects who had prior treatment with dimethyl fumarate (Fumaderm
® or Tecfidera®) or 
any other fumaric  acid ester (FAE) containing products. 
18. Subjects who at Screening and/or randomization have uncontrolled high blood pressure values, which, in the opinion of the Investigator, may increase the risk of cardiovascular events. 
19. Subjects who at Screening have creatinine clearance <60  mL/min. 
20. Subjects who, according to the Reference Laboratory Manual, at Screening have:  
a. White blood cells (WBC) < 3000/mm³ 
b. Neutrophils/granulocytes less than the LLN 
c. Platelets <110,000/ mm³ 
d. Lymphocytes <1000/mm³ 
e. Serum creatinine >1. 5× the upper limit of normal (ULN) 
f. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2×ULN  
g. Significant proteinuria measured as 3+ or above in urine dipstick in two samples taken on two different days 
h. Non-fasted blood glucose > 200 mg/dL 
Note: Laboratory tests that cross these thresholds can be repeated once if the Investigator 
has a clinical reason to believe that a result may be erroneous in which case the laboratory result should be discussed and agreed with the Medical Monitor before repeating it. The repeat value can be accepted if it meets protocol criterion.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 31 - Subjects who have chronically abnormal laboratory values beyond any of the above 
exclusionary thresholds are excluded even if they are deemed clinically normal. 
21. Subjects who have positive results at Screening for hepatitis B (HBsAg and anti- HBc), 
hepatitis C, or human immunodeficiency virus (HIV). 
22. Subjects who have a known immunodeficiency, receive immune modulatory/immune suppressant therapy, or are immunocompromised.  
23. Subjects with malignancy (except for adequately treated basal cell carcinoma, squamous cell carcinoma, and carcinoma in situ of the cervix) or subjects with history of malignancy, with evidence of recurrence within the previous 5 years. 
24. Subjects with a history of drug or alcohol use disorder based on the Diagnostic and Statistical Manual of Mental Disorders (DSM -5) criteria (within the 6  months prior to 
screening) as reported by the subject or known to the Investigator. 
25. Subjects with cognitive deficit or psychiatric  syndrome of any etiology that may influence 
compliance with study procedures or study outcome. 
26. Subjects with a history of allergy to any component of the study drug. 
27. Women who are lactating or breastfeeding.  
28. Investigator site personnel directly affiliated  with this study and/or their immediate 
families. 
29. Sponsor employees or its designee or employees of third-party organizations involved in the study. 
30. Prisoners or subjects who are involuntarily incarcerated. 
 
5.4 Discontinuation of Treatment  or Assessments  
Subjects can be removed from the study for any of the following reasons:  
• AE(s) 
• Protocol violation 
• Withdrawal by subject (subject voluntarily discontinued study participation)  
• Lost to follow-up 
• Pregnancy  
• Study terminated by sponsor 
• Investigator decision 
• Non-compliance with study drug (<80% or >120%)  
• Loss of ability to freely provide consent through imprisonment or involuntary incarceration for treatment of either a psychiatric or physical (eg, infectious disease) illness 
• Unblinding of a subject for any reason  
All subjects meeting the above withdrawal criteria are to be evaluated at the safety follow -up 
EOS visits unless they have withdrawn full consent. The reason for a subject’s permanent 
withdrawal is to be recorded on the appropriate electronic case r eport form (eCRF ). Subjects 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 32 - who prematurely withdraw from the study for AEs are to be monitored for up to 30 days after the 
subject stopped study treatment or until the abnormal parameter resolves  or stabilize s. 
Pregnancies are to be reported to the sponsor or designee within 24 hours of learning of its occurrence, and the pregnancy is to be monitored to determine outcome. Investigators are to 
document their attempts to contact subjects who are lost to follow -up.  
As a class, FAEs are known to have an effect on lymphocyte and eosinophil counts and can have 
hepatotoxic and nephrotoxic effects at excessive exposures. The following study drug 
discontinuation criteria are to be implemented to reduce the risk of toxicity for individual 
subjects and to investigate the time course of recovery of affected safety parameters.  
If any of the following criteria are met, study treatment will be  permanently discontinued and the 
subject will be scheduled for an ETV followed by the Safety Follow- up Visit.  
• Lymphocytes <500/mm
3 at any visit 
• Lymphocytes < 800/mm3 on 3 consecutive visits 
• ALT or AST >8×ULN on repeat examination (if assumed increase is related to study 
drug) 
• ALT or AST >5×ULN for more than 2 weeks on repeat examination (if assumed increase 
is related to study drug)  
• ALT or AST >3×ULN and either total bilirubin >2 × the ULN or International 
Normalized Ratio (INR) >1.5 on repeat examination (if assumed increase is related to study drug) in presence of normal alk phosphate. 
• ALT or AST >3×ULN with concurrent appearance or worsening of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia (>5% eosinophils on differential leukocyte count 
• Serum creatinine >1. 5×ULN on repeat exam  (if assumed increase is related to study 
drug) 
• Proteinuria measured as 3+ or above in urine dipstick on 2 consecutive samples, 4 weeks 
apart 
• If advised by the Medical M onitor or PML experts.  
Laboratory tests can  be repeated earlier than the next scheduled consecutive visit at the 
investigator’s discretion  and any associated safety issue should be followed up as per the 
Investigator’s clinical judgment until resolution/stabilization .  
Replacement Policy  
Subjects who prematurely discontinue from the study afte r randomization will not  be replaced.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 33 - 5.5 Dietary and Lifestyle Restrictions  
Subjects must avoid phototherapy, excessive or prolonged sun exposure, or use of ultraviol et 
(UV) light sources within 28 days of randomization and throughout the study. Subjects will not 
otherwise alter their lifestyle and will not alter their diet during the study except to remain 
compliant with the inclusion and exclusion criteria.  
6. STUDY TREATMENTS  
6.1 Investigational Products and Controls 
The study product under investigation in this study , PPC-06 (tepilamide fumarate) is a prodrug 
of MMF and a member of the FAE class of compounds. It will be administered as an extended 
release (ER) tablet  formulation for oral administration  via blister wallets during the Double -
Blind Titration Period and via bottles during the Double- Blind Treatment Period . Three dosages 
of PPC-06 ER tablets  (400 mg QD , 400 mg BID, and 600 mg BID) and a placebo BID regimen 
(using placebo tablets  identical in  appearance to the active- treatment tablets)  will be studied .  
PPC-06 ER tablets  are white round tablets of 100 mg and 200 mg dose strength, and are 
manufactured and packaged under Good Manufacturing Practice (GMP) regulations. Tablets are 
formulated with PPC-06 and the following excipients: lactose, hypromellose, colloidal silicon 
dioxide, hydroxypropyl cellulose, and magnesium stearate.  
The placebo  tablets will contain the same ingredients as the active formulation(s) without the 
active ingredient , and will be identical in appearance to the active PPC-06 ER tablets . Depending 
on the dose group, subjects are expected to ingest 2.98g to 2.31g of lactose daily from study medication, which is approximately the amount of lactose in ¼ cup of whole milk.  
6.2 Dosing  Regimen  
Dosages and pill allocations for the Titration P eriod (Weeks 1 -5) and for the Treatment Period 
(Weeks 6-24) are shown in Table 6 -1 and Table 6-3, respectively . The dosing regimen for the 
Titration Period is presented  in Table 6-2. Note : Doses specified in red followed by a ‘P’ indicate 
Placebo.  
Double -Blind Titration  Period (Baseline through Week 5) 
Following completion of the pre-randomization Screening Period, eligible subjects will be 
randomized in a 1:1:1:1 ratio to 1 of the 4 treatment arms and will enter the 5-week 
Double-Blind Titration Period.  The first dose of study drug will be taken  the day after the 
Baseline Visit (on Day 1). If a subject misses a dose (or several doses) during the Titration 
Period, they should skip that dose and continue with the next scheduled dose. At least 4 hours should elapse between doses, but ideally 8-12 hour inter vals should be maintained. If a subject 
misses 7 or more consecutive days of dosing during the Titration Period, the site should contact 
the Sponsor or designee for guidance on how to proceed. At Visit 3 ( Week 4), the subjects will 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 34 - be instructed to continue 1 more week of T itration dose (Week 5 of blister wallets) and will also 
be given a kit of bottles which will allow dosing until Visit 4.  Please refer to Table 6-1 for 
titration schedule . 
Double -Blind Treatment Period (Week 6 through Week 24) 
Subjects will receive PPC-06 400 mg QD, PPC-06 400 mg BID, PPC-06 600 mg BID, or 
Placebo BID from Week  6 through Week 24, based on the treatment arm to which they were 
randomized. Subjects will return to the clinic every 4 weeks (±3  days) thereafter for drug 
accountability and to undergo safety and efficacy evaluations per the schedule of assessments 
(Table 1-1). 
• Visit 4: End of Week 8 
• Visit 5: End of Week 12 
• Visit 6: End of Week 16 
• Visit 7: End of Week 20 
• Visit 8: End of Week 24 
• Visit 9: End of Week 25 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 35 - Table 6-1 Treatment Schedule - Titration Period (Weeks 1 -5) 
 400 mg QD 400 mg BID 600 mg BID Placebo  BID 
Week 1 
(Days 1-7) 100 P (am)  + 100 P (am)  
100 P (pm)  + 100 (pm)  100 P (am) + 100 P (am)  
100 P (pm) + 100 (pm)  100 (am) + 100 P (am)  
100 P (pm) + 100 (pm)  100 P (am) + 100 P (am)  
100 P (pm) + 100 P (pm)  
Week 2 
(Days 8-14) 200 P (am) + 200 P (am)  
200 P (pm) + 200 (pm)  200 P (am) + 200 P (am)  
200 P (pm) + 200 (pm)  200 (am) + 200 P (am)  
200 P (pm) + 200 (pm)  200 P (am) + 200 P (am)  
200 P (pm) + 200 P (pm)  
Week 3 
(Days 15-21) 100 P (am) + 100 P (am)   
200 (pm) + 200 (pm)  100 P (am) + 100 (am)   
200 P (pm) + 200 (pm)  100 (am) + 100 (am)   
200 (pm) + 200 (pm)  100 P (am) + 100 P (am)   
200 P (pm) + 200 P (pm)  
Week 4 
(Days 22-28) 200 P (am) + 200 P (am)    
200 (pm) + 200  (pm) 200 P (am)  + 200 (am)   
200 P (pm)  + 200 (pm) 200 (am) + 200 (am)  
200 (pm) + 200 (pm)  200 P (am) + 200 P (am)  
200 P (pm) + 200 P (pm)  
Week 5 
(Days 29-35) 200 P (am)  + 200 P (am)   
200 (pm) + 200  (pm) + 200 P (pm)  200 P (am)  + 200 (am)   
200 (pm) + 200 (pm) + 200 P (pm)  200 (am) + 200 (am)  
200 (pm) + 200 (pm) + 200 (pm)  200 P (am) + 200 P (am)  
200 P (pm) + 200 P (pm) + 200 P (pm)  
Table 6-2 Titration Regimen  
Visit  Weeks (Days)  Tablet regimen for all groups  
Baseline* Week 1 (Days 1 -7) Take 2 tabs in the morning and 2 tabs in the evening from the blister  
Week 2 (Days 8 -14) Take 2 tabs in the morning and 2 tabs in the evening from the blister  
Week 3 (Days 15 -21) Take 2 tabs in the morning and 2 tabs in the evening from the blister  
Week 4 (Days 22 -28) Take 2 tabs in the morning and 2 tabs in the evening from the blister  
Week 5 (Days 29 -35) Take 2 tabs in the morning and 3 tabs in the evening from the blister  
Week 4# (Day 28) Week 6 (Days 36 -42) to 
Week 8 (Days 50 -56)  Take 1 tab from AM Bottle 1 and 2 tabs from AM Bottle 2; repeat the process in the night with PM bottles.  
* = Subjects will be given 5 blister wallets  (for Weeks 1 -5) 
# = Subjects will be given 2 sets of 2 Bottles as mentioned.  
Table 6-3 Treatment Schedule: Treatment Period (Weeks 6 -24) 
Visit  PPC -06 400 mg QD Regimen  PPC -06 400 mg BID Regimen  PPC -06 600 BID Regimen  PPC -06 Placebo BID Regimen  
 Week 6 – Week 24 Week 6 – Week 24 Week 6 – Week 24 Week 6 – Week 24 
Weeks 8-20 
(Dispense 2 sets 
of 2 Bottles)1  
200 P (am) + 200 P (am) + 200 P (am)  
200 (pm) +  200 (pm) + 200 P (pm)   
200 P (am) + 200 (am) + 200 (am) 
200 (pm) +  200 (pm) + 200 P (pm)  
200 (am) +  200 (am) + 200 (am)  
200 (pm) + 200 (pm) + 200 (pm)   
200 P (am) + 200 P (am) + 200 P (am)   
200 P (pm) + 200 P (pm) + 200 P (pm)  
1 Subjects will be given 2 sets of 2 bottles (2 morning (AM) bottles + 2 evening (PM) bottles ) 
AM Bottles: AM Bottle 1 (30 count) and AM Bottle 2 (60 count)  
PM Bottles: PM Bottle 1 (30 count) and PM Bottle 2 (60 count)  
Take 1 tablet from (AM) Bottle 1 and 2 tablets from (AM) Bottle 2; repeat the process in the evening with (PM) bottles  
 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 36 - 6.3 Dose Modification 
At any point during the Double- Blind Titration or  Treatment Period s, a temporary dose reduction 
or interruption may be considered in circumstances where a subject has a tolerability issue such 
as flushing or GI intolerance. The Investigator may use other medications such as loperamide for 
diarrhea (or local standard of care) for tolerability management as long as the medication is not one of the prohibited/restricted medications.  
During the Double- Blind Treatment Period (Weeks 6 -24), in the event of a temporary dose 
reduction (no more than 2 weeks), 1 tablet from each Bottle 2 (AM and PM) will be reduced. 
When the tolerability issues resolve, study drug should be titrated back up to the respective 
treatment dose. If the tolerability issues return at the higher dose, subjects may be discontinued 
from the study. 
Note: Subjects who discontinue study treatment for more than 2 weeks  during the Double-Blind 
Titration or Treatment Periods  due to tolerability issues or for any other reason at any po int 
during the study will not be allowed to resume their study treatment and will be scheduled for an 
ETV. Subjects who discontinue from the study for any reason at any time point will directly 
continue to the ETV.  
6.4 Packaging and Labeling 
The IP will be labeled according to all applicable federal regulations and be printed in the local 
language.  
The study medication will be supplied to the clinical site(s)  in kits containing 5 weeks of blister 
wallets which will be used for the Titration Period, as well as  kits containing 2 sets of 2 Bottles 
which will be used for the Treatment Period. The blister wallet kits will contain a total of 147 
tablets, and the Bottle kits will contain 2 AM and 2 PM bottles: 
• AM Bottle 1 – 30 tablets 
• AM Bottle 2 – 60 tablets 
• PM Bottle 1 – 30 tablets 
• PM Bottle 2 – 60 tablets  
6.5 Storage 
Investigational product must be stored at controlled room temperature (20-25°C, 68-77°F) with 
excursions permitted to 15°-30°C (59°-86°F). Subjects will be advised to keep study medication out of reach of children and persons who may not be able to read or understand the label. All 
study medication should be kept in a secure area inaccessible to unauthorized individuals. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 37 - All remaining IP will be returned to the sponsor or its designee after final drug accountability has 
been completed.  
6.6 Assign ment  to Treatment 
6.6.1 Randomization 
All subjects who enter into the screening period for the study (defined as the point at which the subject signs the ICF) will receive a subject identification number through the Interactive Web 
Response System (I WRS). This number (which will consist of the site number followed by the 
subject number) will be used to identify the subject throughout the study and must be used on all 
study documentation related to that subject. The su bject identification number must remain 
constant throughout the entire study; it must not be changed at the time of screening or 
randomization. This number will not be the same as the assigned randomization number. The IWRS will be used for randomization. A subject can be rescreened on a case by case basis with 
input from the Medical Monitor. In the event a subject is rescreened, the subject will be 
(re)presented with the ICF and a new subject identification number will be given by IWRS. 
Once assigned to a subject, a subject identification number will not be reused . If the subject fails 
to be randomized for any reason, the reason for not being randomized will be entered in the subject’s eCRF.  
The randomization scheme will be reviewed and approved by a member of the sponsor’s 
Biostatistics and Data Management (BDM) group or designee. The sites will randomize eligible 
subjects by contacting I WRS at Visit 2 after all of the relevant Baseline procedures are 
completed and assessed as appropriate. A subject who fulfills the study eligibility requirements 
will be randomly assigned to treatment. The randomization will be stratified by prior biologic use. 
The IWRS will assign a randomization number to th e subject, which will be used to link the 
subject to the treatment group and will specify a unique Blister Wallet IP kit number for the IP to 
be dispensed to the subject at Visit 2 for the Titration Period . The sites will log in to IWRS 
during each subsequent subject visit to obtain the kit numbers of the Bottle Kits to be dispensed at study Visits 3-7. 
6.6.2 Blinding  
This is a double-blind study. The investigator, study coordinator(s), subjects and the Sponsor 
study team and its representatives, will be blinded to the identity of the randomized treatment 
assignment from the time of randomization until database lock. Randomization data will be kept 
in strict confidence by the statistician who generated the randomization schedule, the IW RS 
provider, and the vendor involved in the IP labeling. All active and placebo IP will be of 
identical appearance, regardless of the dose. Study materials will be packaged and issued in a manner designed to maintain the blind. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 38 - Unblinding by study site personnel for AEs should only be performed in an emergency, when 
knowledge of the subject’s treatment assignment is essential for the clinical management or 
welfare of the subject (Section 13.1, Emergency Unblinding).  
Prior to unblinding, the investigator should make every effort to first contact the Medical 
Monitor (or designee ) and should assess the relationship of an AE  to the administration of the IP. 
The investigator must then log in to  the IWRS to unblind the individual subject’s treatment 
assignment . If the blind is broken for any reason, the investigator must record the date and reason 
for breaking the blind on the appropriate e CRF and source documents. 
For details of the procedure for unblinding of individual subjects in cases of emergency see Section 13.1. 
6.7 Prior and Concomitant Therapy  
All medica tions, including over-the-counter (OTC) drugs, taken within 30 days prior to the start 
of the study (Screening Visit) will be recorded at Screening. Thereafter, a record of all 
medications and supportive therapy taken during the course of the study will be made. Information regarding the total daily dose, route of administration, start and discontinuation 
dates, and indication are to be recorded on the subject’s e CRF. 
Changes to medications, including prescription, OTC , herbal preparations, or mineral 
supplements taken for treatment of psoriasis will not be allowed without prior approval of the 
Medical Monitor or designee. Use of hormonal contraceptives is to be stabilized for at least 
3 months prior to randomization.  
The use of non- medicated emollients is permitted during the study; every effort is to be made to 
maintain the same regimen following Screening and throughout the study. The use of color-
cosmetics and sunscreens/sunblocking agents is allowed; however, excessive and/or prolonged exposure to direct sun must be avoided during the trial. 
The use of non- steroidal anti -inflammatory drugs (NSAIDs) or analgesic treatments will be 
permitted to treat symptoms of psoriatic arthritis on a PRN basis.  
Restrictions regarding prior and concomitant therapies, as listed in the Exclusion Criteria , must 
be observed during the study, including the treatment and follow-up periods. Dose adjustments 
of any permitted concomitant medications should be avoided during the study, if possible. 
The following therapies are p rohibited from use at any time during the study:  
• Any drug known to influence the course of psoriasis such as lithium, beta-blockers, and 
antimalarial therapies  
- Stable doses of beta-blockers are permitted if there is no history of exacerbation of psoriasis due to beta-blockers and the dose will be kept unchanged throughout the trial. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 39 - • Any live vaccines, except flu vaccines.  
• Any systemic non -biologic immunosuppressive medication ( eg, MTX, cyclosporine, 
mycophenylate mofetil, 6 -thioguanine) 
• Biologic agents ( eg, etanercept, alefecept) and any antibody ( eg, infliximab, adalimumab, 
golimumab, ustekinum ab) 
• Any systemic steroid (steroid inhalers , nasal sprays  and eye drops or intra -articular 
injections are permitted)  
• Phototherapy 
• Laser therapy for pso riasis or oth er skin conditions 
• Topical corticosteroids (other than the limited use of mild topical steroids specified below 
under “Rescue Medication”), vitamin D analogs, tar preparations, salicylic acid, or urea preparation s 
• Topical or systemic calcineurin inhibitors  (eg, tacrolimus, pimecrolimus)  
• Topical or systemic retinoids ( eg, tazarotene, tretinoin, adapalene)  
• Topical (ointment and/or baths) or oral fumaric acid derivatives  
• Cytostatic drugs ( eg, cyclophosphamide, ifosfamide, vinblastine, vincristine, procarbazine, 
dacarbazine, 6 -mercaptopurine, 5- fluorouracil, adriam ycin) 
• Any investigational drug or therapy, or approved drug or therapy for investigational use 
 
Rescue and C oncomitant M edication  
The use of rescue medications for the treatment of psoriasis may be permitted during the Double-
Blind Titration and/or Treatment Period  at the investigator’s discretion. Subjects will be  
considered a treatment failure if rescue therapy is required; however, they can continue for safety 
monitoring, if required. Concomitant medications permitted for use for psoriasis are restricted to bland emollients and other non- medicated interventions . This excludes any topical agents that 
contain pharmacologically active ingredients ( eg, salicylic acid, alpha -hydroxy acids, urea, etc.) . 
Dose adjustments of any permitted concomitant medications should be avoided during the study, if possible.   
Note: Limited use of mild topical steroids (Class VI or VII in North America) for the treatment 
of psoriasis on limited areas (face, axilla,  and/or genitalia) is permitted . Subjects will be 
permitted to use medicated shampoos (on the scalp only in the shower). This will not be 
considered as rescue medication.  
6.8 Treatment Compliance  
Subject compliance with study drug will be assessed by the inves tigator and/or study personnel 
at each visit using direct questioning, and pill counts. Deviations from the prescribed treatment regimen will be recorded on the source document and the subjects’ eCRF s. All returned blister 
wallets or bottles must be reviewed at every visit while the subject is still at the clinic to 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 40 - determine if the subject is dosing as instructed . Deviations from the prescribed treatment regimen 
will be recorded on the source document and the subjects’ eCRFs.  
During the T itration Period, if a subject misses a dose (or several doses), they should skip that 
dose and continue with the next scheduled dose. If a subject misses 7 or more  consecutive days 
of dosing during the Titration Period, the site should contact the Sponsor or designee for 
guidance on how to proceed.  
During the Double-Blind Treatment Period, a subject is said to be compliant if they have taken 
80% to 120% of the expe cted tablets of study medication . If a subject has taken less than 80% or 
more than 120% of the expected tablets since the last visit, the subject should be counseled . In 
cases where noncompliance is continual, the site should contact the study Medical Mon itor or 
designee to discuss other options, such as withdrawing the subject. 
Compliance calculation has been defined in Section 8.5. 
7. VISIT SCHEDULE AND ASSESSMENTS  
7.1 Study Procedures  
The visit schedule and assessments are summarized in Table 1-1.  
7.2 Study Visits and Assessments  
7.2.1 Visit 1 Screening  (Day -28 to Day -1)  
Screening of subjects  will start at Visit 1 and continue up to 4 weeks prior to Baseline/  
Randomization (Visit 2)  unless an extension is granted by the Medical Monitor in advance of the 
Visit 2. Screening procedures will include:  
• Review study information with subject and obtain written informed consent 
• Register subject in I WRS to receive Screening Number  
• Review inclusion and exclusion criteria with the subject to determine the subject’s 
eligibility  
• Perform psoriasis assessments to ensure that subject will meet PASI, IGA, and BSA 
requirements  at Baseline visit  
• Collect medical history and demographic information 
• Collect psorias is medical history and use of all prior medications and non-drug therapies to 
treat psoriasis  
• Review and record prior medication s (used within the previous 30 days) and concomitant 
medication s (medicati ons currently used) 
• Perform a complete physical examin ation, including height, weight , and waist 
circumference  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 41 - • Measure vital signs (systolic and diastolic blood pressure, heart rate, and respiratory rate) 
with subject in a seated position  
• Obtain a 12 -lead ECG 
• Obtain blood and urine samples for routine laborat ory profile evaluations including 
hematology, serum chemistry, and urinalysis  
• Obtain samples for se rology: human immunodeficiency virus (HIV ), hepatitis B virus  
surface antigen  (HBsAg), antibodies to hepatitis B core antigen ( anti-HBc), and hepatitis C 
virus (HCV) 
• Obtain a sample for a serum  pregnancy test for all female subjects . Instruct all female 
subjects to use approved form(s) of contracepti on  
• Record any SAEs (from time of signing ICF)  
• If subject meets the inclusion/exclusion criteria , instruct the subject to begin washout of 
prohibited medications and s chedule Visit 2  pending receipt of lab and ECG results 
7.2.2 Visit 2 – Randomization/ Baseline  (Day 0) 
• Perform psoriasis assessments:  
• PASI, BSA, IGA 
• NAPSI for fingernails , PSSI, PP P GA for all subjects; if score is 0 at Baseline for any 
of these assessments, then the respective assessment (s) would not be required to be 
completed at future study visits  
• Confirm psoriasis medical history and previous psoriasis therapies 
• Confirm medical history and record any new findings 
• Review and record medication changes  since the Screening visit , including c hanges in 
prescription and OTC  medications, herbal preparations, and vitamin and/or mineral 
supplements and non- drug therapies  
• Confirm wa shout of prohibited medications 
• Perform a partial physical examination  with focus on previously noted abnormalities in 
organ systems, including skin 
• Measure vital signs (systolic and diastolic blood pressure, heart rate, and respiratory rate) with subject in a seated position  
• Obtain a 12- lead ECG  (Baseline Visit central ECG reading will not be available prior to 
Randomization; Investigator must review Baseline ECG tracing to confirm eligibility  prior 
to Randomization. Subject with clinically significant ECG findings in the Investigator ’s 
opinion will be screen failed. Investigator also must review the central ECG reading  when 
results are available. Subjects with unacceptable ECG findings will be discontinued from the study) 
• Review inclusion and exclusion criteria to confirm  that the subject is qualified for study 
participation  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 42 - • Perform a urine pregnancy test  for female subjects of childbearing potential . Instruct all 
female subjects to use approved form(s) of contraception  
• Obtain blood and urine samples for routine laboratory profile evaluations including 
hematology, serum chemistry, and urinalysis 
• Blood collection for PD  study as well as lymphocyte & Ab titer  study 
• Record any SAEs 
• Have the subject complete the following assessments:  
• Pruritus NRS, DLQI, SF-12, QIDS-SR16, WPAI: PSO, HEOR 
• Perform photography (at selected 3 sites only) ; see photography reference materials for 
details 
• Randomize the subject in IW RS after confirmation of eligibility criteria  
• Instruct subjects on dosing and dispense study drug 
• Dispense educational materials for AE management (provided by Sponsor) 
• Provide subject with Bristol Stool Chart ; have the subject confirm the average frequency of 
their bowel movements for the past 15 days and the general consistency of the stool using 
the Bristol Stool Chart  
7.2.3 Visit 3  (Week  4), Visit 4 (Week 8), Visit 5 (Week 12), Visit  6 (Week 16 ), Visit 7 
(Week  20), and Visit  8 (Week  24) 
• Review any concomitant medication changes since the previous study visit 
• Perform a partial physical examination with focus on previously noted abnormaliti es in 
organ systems, including skin 
• Measure weight  
• Measure waist circumference (Week 24 only)  
• Measure vital signs (systolic and diastolic blood pressure, heart rate, and respiratory rate) with subject in a seated position  
• Record a 12 -lead ECG  
• Obtain blood and urine samples for routine laboratory profile evaluations including hematology, clinical chemistry, and urinalysis  
• Blood collection for PD  study 
• Blood collection for lymphocyte subset & Ab titer study (Week 24 , or at any time during 
the study if subject shows signs of PML) 
• Perform a UPT for females of childbearing potential. Ensure that female subjects of 
childbearing potential are using approved method(s) of contraception. 
• Record any AEs  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 43 - • Perform psoriasis assessments  if applicable:  
• PASI, BSA, IGA 
• NAPSI for target fingernail , if applicable (weeks 12, 16 and 24 only) 
•  PSSI, PP P GA (if applicable )  
• Have the subject perform the following assessments:  
• Pruritus NRS  
• DLQI, SF -12, QIDS -SR16, WPAI: PSO, HEOR (Weeks 12, 16, and 24 only) 
• Perform photography (at selected 3 sites only) (Weeks 12 , 16, and 24 only) ; see 
photography reference materials for details  
• Assess IP compliance/accountability   
• Dispense IP  as applicable (Weeks 4, 8, 12, 16, and 20) 
7.2.4 Early Termination Visit  
• Review any conco mitant medication changes since the previous study visit 
• Assess IP compliance/accountability   
• Perform a partial physical examination with focus on previously noted abnormalities in 
organ systems, including skin 
• Measure weight  
• Measure waist circumference  
• Measure vital signs (systolic and diastolic blood pressure, heart rate, and respiratory rate) 
with subject in a seated position  
• Record a 12 -lead ECG  
• Perform a UPT for females of childbearing potential. Ensure that female subjects of 
childbearing potential ar e using approved method(s) of contraception. 
• Obtain blood and urine samples for routine laboratory profile evaluations including hematology, clinical chemistry, and urinalysis  
• Blood collection for lymphocyte subset & Ab titer study 
• Record any AEs 
• Perform p soriasis assessments:  
• PASI, BSA, IGA 
• NAPSI for target fingernail , PSSI, PP P GA (if applicable)  
• Have the subject perform the following assessments:  
• Pruritus NRS 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 44 - • DLQI, SF -12, QIDS -SR16, WPAI: PSO, HEOR 
7.2.5 Safety Follow- up Visit  (Week 25  [+3 days], or 1 Week  [+3 days] after ETV, 
unless final dose was taken >7 days prior to Week 24/ETV) 
• Review any concomitant medication s used since the previous study visit 
• Perform a partial physical examination with focus on previously noted abnormalities in 
organ systems, inc luding skin 
• Measure vital signs (systolic and diastolic blood pressure, heart rate, and respiratory rate) with subject in a seated position  
• Record a 12 -lead ECG  
• Perform a UPT for females of childbearing potential. Ensure that female subjects of 
childbearin g potential are using approved method(s) of contraception. 
• Record any AEs  
• Perform psoriasis assessments:  
• PASI, BSA, IGA 
• NAPSI for the target finger nail , PSSI, PP P GA (if applicable)  
• Have the subject perform the following assessments:  
• Pruritus NRS 
• DLQI, SF-12, QIDS -SR16, WPAI: PSO, HEOR 
7.2.6 Unscheduled Visit  
If a subject returns to the site for an unscheduled visit, the following assessments may  be 
performed  at the discretion of the Investigator: 
• Review any concomitant medication s used since the previous stud y visit 
• Perform a partial physical examination with focus on previously noted abnormalities in organ systems, including skin 
• Measure weight  
• Measure vital signs (systolic and diastolic blood pressure, heart rate, and respiratory rate) with subject in a seat ed position 
• Obtain blood and urine samples for routine laboratory profile evaluations including 
hematology, clinical chemistry, and urinalysis  
• Record any AEs 
7.3 Efficacy  Assessments  
Efficacy will be evaluated via psoriasis assessments and measures of QoL.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 45 - Psoriasis assessments include the PASI, the affected BSA, and the IGA. Subject-reported 
assessments of health-related QoL include the DLQI, 12- Item Short Form Survey (SF -12), the 
Quick Inventory of Depressive Symptomatology- Self Report (QIDS -SR), the WPAI:PSO, the 
HEOR, and the Pruritus NRS.  
Other psoriasis assessments to be performed as applicable include the NAPSI for the target 
fingernail , the PSSI score, and the PP P GA score. 
Brief descriptions of these assessments are presented as follows. 
7.3.1 Co-Primary Efficacy Assessment s: Psoriasis Area and Severity Index  and 
Investigator’s Global  Assessment  
The investigator or designee will assess the extent and severity of the subjects’ psoriasis using 
the PASI scoring system  and will perform a global assessment of d isease severity using the IGA. 
The PASI scale is provided in  Appendix 1; the IGA is a 5-point scale which measures the 
investigator’s or designee’s impression of the disease at a single point. Assessments will be performed at the visits specified in Table 1-1. Sites should make every effort to ensure 
consistency in evaluators across visits, especially between Baseline and Week 24.  
Psoriasis Area and Severity Index  
The PASI is a measure of the average redness, thickness, and scaliness of the lesions (each graded on a 0–4 scale) and weighted by the ar ea of involvement ( Fredriksson, 1978). There are a 
few validation studies performed describing, with some limitations, the construct validity, face validity, and sensitivity to change ( Ashcroft, 1999). National Psoriasis Foundation Medical 
Advisory Board standardized the definitions of events of psoriasis recurrence based on PASI, including the definition of relapse, which is a loss of at least 50% of PASI improvement after discontinuation of treatment in patients who had achieved a clinically meaningful response; and rebound, which is PASI ≥125% of Baseline or new generalized pustular, erythrodermic, or more inflammatory psoriasis ( Carey, 2006; Gordon, 2005). In the current trial , PASI improvement will 
be evaluated from Baseline to all visits during the Titration and Treatment Periods , and clinically 
meaningful response is defined as PASI- 50 (Carlin, 2004).  
Investigator’s Global Assessment  
The IGA should be performed by the same evaluator (rater) who performs the PASI assessments  
and all efficacy assessments should be performed by the same evaluator throughout the study 
when possible. The scale in Table 7-1 will be used  for the IGA assessment :  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 46 - Table 7-1 Investigator’s Global Assessment ( IGA ) 
Score  Grade  Definition  
0 Clear No signs of psoriasis  
Post-inflammatory hyperpigmentation may be present  
1 Almost 
clear No thickening to minimal plaque elevation  
Normal to slight pink coloration/faint erythema  
Focal to minimal scaling  
2 Mild Slight elevation/thickening  
Pink to light red coloration  
Predominantly fine scaling partially or mostly covering lesions  
3 Moderate  Clearly distinguishable/distinct thickening  
Definite red coloration  
Coarse scaling covering most plaques  
4 Severe Marked thickening with hard/sharp edges  
Bright to deep dark red coloration 
Thick/coarse scaling covering almost all or all lesions  
Adapted from:  Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, et al. The 5 -point Investigator’s 
Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J 
Dermatolog Treat. 2015;26(1): 23- 31. 
 
7.3.2 Secondary Efficacy A ssessment s 
Secondary efficacy assessments will be performed at the visits specified in Table 1-1. 
7.3.2.1 Affected Body Surface Area  
BSA will be calculated us ing handprint methodology, comparing the size of the affected area to 
the size of the subject’s  entire handprint, which equates to approximately 1% BSA. Evaluator s 
should use the method consistently throughout the trial.  7.3.2.2 Nail Psoriasis Severity Index  
The NAPSI is a numeric, reproducible, objective, simple tool for evaluation of nail psoriasis. 
This scale is used to evaluate the severity of nail bed psoriasis and nail matrix psoriasis by area 
of involvement in the nail unit. The NAPSI is provided in Appendix 2.  
7.3.2.3 Psoriasis Scalp Severity Index  
The PSSI is a grading system for scalp psoriasis, which is similar to the PASI for generalized 
psoriasis. The scale for PSSI ranges from 0 (absent) to 4 (very severe) for each of the three categories of erythema, desquamation and thickness, which are rated separately. The individual 
scores are then added and multiplied by a number based on the area of the scalp that i s covered 
by psoriasis. The final PSSI score can range from 0 to 72.  
The PSSI is provided in Appendix 3. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 47 - 7.3.2.4 Palmoplantar Psoriasis Physician’s Global Assessment  (PP PGA)  
The investigator or designee will assess the subject’s palmar and plantar surfaces using t he PP 
PGA score. The PP  PGA is provided in Appendix 4.  
7.3.2.5 Pruritus Numerical Rating System  
The subject will be asked to rate the intensity of their pruritus using the Pruritus NRS. The 
Pruritus NRS will be used to assess pruritus intensity over the previous 24 hours . It is a 
commonly used instrument with demonstrated high reliability and concurrent validity ( Phan, 
2012; Reich, 2009). The NRS records the subject’s perceptions of their pruritus and can be used 
to monitor changes over time. 
7.3.3 Health-related Quality of Life Assessment s 
Health-related QoL  assessments will be performed at the visits specified in  Table 1-1. 
7.3.3.1 Dermatology Life Quali ty Index  
The subject will be asked to complete the DLQI, which is a validated questionnaire consisting of 
10 questions relating to the degree to which the subject’s skin condition affects their daily 
activities (Finlay 1994). The DLQI is provided in Appendix 5. 
7.3.3.2 12-Item Short Form Survey  
The SF-12 questionnaire contains a set of generic, coherent, and easily administered patient -
reported quality- of-life measures that are useful for the monitoring and assessment of care 
outcomes in adult subjects . The SF-12 is provided in Appendix 6. 
7.3.3.3 Quick Invent ory of Depressive Symptomatology- Self Report (16 Items)  
The Quick Inventory of Depressive Symptomatology – Self Report is a questionnaire designed to 
be filled out by the subject to assess the severity of depressive symptoms. The Quick Inventory of Depress ive Symptomology – Self Report  is provided in Appendix 7. 
7.3.3.4 Work Productivity and Activity Impairment Questionnaire: Psoriasis 
The Work Productivity and Activity Impairment (WPAI) questionnaire is an instrument designed to measure impairments in work  and in activities.  
The Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI:PSO) is provided in Appendix 8. 
7.3.3.5 Health Economics and O utcomes Research  
The HEOR evaluation will be performed by asking three questions at Baseline, Week 12 , Week 
16, Week 24/ETV, and Week 25 Visit. The questions are the following: 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 48 - • Baseline visit  
o How many times, in the past 3 months, have you been to any phys ician's office or 
urgent care clinic?  
 Please state reason for each visit 
 
o How many times, in the past 3 months, have you seen a nurse practitioner, a 
physician assistant, a psychologist, a naturopath, an acupuncturist, a chiropractor, or other healthcare professional (HCP) ?  
 Please state reason for each visit 
 
o How many times, in the past 3 months, have you received care from a health professional in your home? 
  Please state reason for each visit 
 
• 12 weeks, 16 weeks, 24 weeks and 25 weeks  
o How many times, since you started the study medication, have you been to any physician's office or urgent care clinic, other than the regular assessment appointments as part of the clinical trial?  
 Please state reason for each visit 
 
o How many times, since you started the study medication, have you seen a nurse practitioner, a physician assistant, a psychologist, a naturopath, an acupuncturist, a chiropractor, or other healthcare professional (HCP) ?  
 Please state reason for each visit 
 
o How many times, since you started the study medication, have you received care from a health professional in your home?  
 Please state reason for each visit 
 
7.4 Assessment of Pharmacokinetics  
No pharmacokinetics determinations will be assessed during this study. 
7.5 Assessment of Safety  
7.5.1 Adverse Events  
7.5.1.1 Adverse Events Assessments  
An AE is an untoward medical occurrence in any subject during the study which does not 
necessarily have a causal relationship with the study drug treatment. Adverse events can be 
categorized as treatment -emergent or treatment -related. All AEs will be recorded and will be 
documented in the e CRF and will be captured from the time of intake of study drug. All serious 
adverse events (SAEs) will be captured from the time of signing the ICF and must be reported to 
the sponsor within 24 hours of awareness. The condition of the subject  will be monitored 
throughout the study for any signs or symptoms. The occurrence of AEs should be sought by 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 49 - nondirective questioning of the subject  at each visit during the study. All AEs will be collected 
as: 
• The subject ’s response to questions about their health 
• Symptoms spontaneously reported by the subject 
• Clinically relevant changes and abnormalities observed by the investigator (eg, local and 
systemic tolerability, laboratory measurements, re sults of ph ysical examinations)  
If a Medical History condition worsens or increases in frequency after the first dose of IP, it 
should be recorded as an AE in the eCRF. If an AE worsens in intensity, it should be recorded as 
a new AE. Otherwise, it continues as the f irst report  (counted as the same AE)  until the subject is 
recovered.  
The investigator or designee will record the following on the AE eCRF: 
• AE and relevant clinical findings 
• Time/date of onset  
• Time/date of recovery  
• Intensity 
• Action taken on study drug/treatment 
• Other action taken to treat the event  
• Relation to study drug/treatment  
• Seriousness of the AE 
AEs requiring therapy must be treated with recognized standards of medical care to protect the 
health and well -being of the subject. Treatment due t o an AE will be recorded.  
Subjects who prematurely withdraw from the study for AEs are to be monitored for up to 30 days after the subject stopped study treatment or until the abnormal parameter resolves or 
stabilizes.  
The outcome of an AE will be classif ied as recovered, recovered with sequelae, not yet 
recovered , or death.   
7.5.1.2 Timing  
Adverse events will be assessed at  all study visits . Adverse events should be monitored by the 
investigator for up to 30 days after the subject has stopped study treatment or until the AE has 
resolved or stabilized. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 50 - Treatment -emergent AEs (TEAEs) include any untoward medical occurrence in a patient/subject 
or clinical investigation subject after administration of an investigational study treatment, which 
does not necessarily have to have a causal relationship with this treatment. A TEAE  can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of the product, whether or not related to the medicinal (investigational) product. It could also include accidents and reasons for changes in 
medication (drug and/or dose), any medical, nursing or pharmacy consultation, or admission to 
hospital or surgical operations. Record TEAEs that occur after the first dose through 5 days after 
the last dose.  
Treatment -related AEs are all TEAEs that are considered by the investigator as causally related 
to administration o f the study drug. 
7.5.1.3 Severity  of Adverse Events  
The investigator is to classify the severity (intensity) of an AE according to the following 
definitions: 
• Mild – The subject was aware of the signs and symptoms but the signs and symptoms 
were easily tolerated.  
• Moderate – The signs and symptoms were sufficient to restrict, but did not prevent, usual 
daily activity for the subject.  
• Severe – The subject was unable to perform usual daily activity. 
The maximum intensity of an AE (mild, moderate, or severe) will be assessed taking into account the possible range of intensity of the symptom(s). 
The severity of diarrhea and lymphocytopenia will be graded using a modified common 
terminology criteria for adverse events (CTCAE), Version 4.03 (see Appendix 9) . If the subject 
reports that they are experiencing diarrhea, they will be presented with the Bristol Stool Chart 
and asked to identify the consistency ( see Bristol Stool Chart Appendix 10 ). Only Type 7 on the 
Bristol Stoo l Chart is considered diarrhea.  The frequency of Type 7 diarrhea is then used to 
determine the CTCAE grade.  All subjects will be provided with educational materials at Baseline 
to help prepare them for the potential GI- related adverse events.  All subjects will be asked at 
Baseline to assess the average frequency of their bowel movements for the past 15 days and the 
general consistency of the stool using the Bristol Stool Chart.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 51 - 7.5.1.4 Relationship  of an Adverse Event  to Study Treatment  
The investigator is to classify the relationship of an AE to the IP using good clinical judgment 
and the following definitions: 
Not Related  The AE is clearly explained by another cause not related to the study 
product 
Probably Not Related  A potential relationship between study product and the AE could exist 
(ie, the possibility cannot be excluded), but the AE is most likely 
explained by causes other than the study agent 
Possibly Related  The AE and administration of study product are tempor ally related, but 
the AE can  be explained equally well by caus es other than the study 
product 
Probably Related  The AE and use of study product are temporally related, and the AE is 
more likely explained by study product than by other causes  
Definitely Related The AE and use of study product are related in time, and a direct 
association can  be demonstrated  
Adverse events commonly observed in previous clinical studies with PPC -06 include GI  
disorders, including diarrhea, nausea, and abdominal pain, and flushing. As a class, FAEs are 
known to have an effect on lymphocyte and eosinophil counts. Reversible lymphopenia and transient eosinophilia are frequently observed with both Fumaderm and Tec fidera treatment.  
7.5.1.5 Adverse Event of Special Interest (AESI)  
If the subject complains of any kind of neurological symptoms (such as aphasia, clumsiness, weakening of arms and legs or any new neurological signs or symptoms) during the scheduled study visits or at any time point during the study, the subject will be evaluated at the site for any neurological dysfunction. If the site evaluation for neurological dysfunction is positive or equivocal, the subject will be referred to a neurologist for consultation. If the subject is negative 
for PML after examination by the neurologist, the subject will continue in the study. If required, 
the PML experts will be consulted to assess and monitor, as the case may be. The study drug will be stopped in the subject only if recommended by the PML expert.  
Stopping Rules: 
The potential event of PML will be carefully managed by utilizin g the below stopping criteria. If 
one or more of the below criteria are met, study drug will be permanently discontinued and the 
subject will b e scheduled for an ETV followed by Safety Follow-up visits 1 week (± 3 days) 
after the last dose of study drug. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 52 - • Lymphocytes <500/mm3 in one reading; 
• Lymphocytes <800/mm3 in 3 consecutive visits 4 weeks apart; Lymphocyte count can be 
repeated in the interim  period. If the interim lymphocyte counts are higher than 
800/cu.mm, then the PI with concurrence from Medical monitor, will decide if the 
subjects should stay in the study or discontinued from the study. 
• When recommended by the PML expert.  
Blood collection for lymphocyte subset & Ab titer  can be collected at any study visit if the 
subject shows signs of PML. 
7.5.2 Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose:  
• results in death  
• is life-threatening  
• requires in -patient hospitalization or prolongation of existing hospitalization  
• results in persistent or significant disability/incapacity  
• is a congenital anomaly/birth defect, or is an important medical event 
The death of a subject  enrolled in a study is per se not an event, but an outcome. Any event 
resulting in a fatal outcome must be fully documented and reported, regardless of the causality 
relationship to the IP. 
The term life -threatening refers to an AE in which the subject  was at immediate risk of death at 
the time of the event. It does not refer to an event, which may have caused death, if it was more 
severe. 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the subjec t or may require 
intervention to prevent one of the other outcomes listed in the definition above. These should 
also usually be considered serious. Examples of important medical events include AEs, which suggest a significant hazard, contraindication or precaution, occurrence of malignancy, or 
development of drug dependency or drug abuse. 
Any SAE, whether or not deemed drug- related or expected,  must be reported immediately to the  
sponsor’s designee as soon as it becomes known to the investigator and not later than within 24 
hours of his/her knowledge of the occurrence of an SAE. The investigator will document such 
events in the best possible detail on the SAE Report Form to be transmitted to the  sponsor’s 
designee.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 53 - An IND Safety Report (INDSR)  is an SAE that is both unexpected (not consistent with the 
current Investigator’s Brochure/product information) and for which there is evidence to suggest a 
causal relationship between the drug and the AE. The Institutional Review Board ( IRB) will be 
informed of INDSRs according to local requirements. All investigators participating in the trial 
will also be notified of unexpected SAEs. The sponsor will report SAEs and other events 
requiring expedited reporting to regulatory authorities as required.  
Investigator instructions for reporting SAEs  are provided in Section 13.2. 
7.5.3 Safety  Laboratory Assessments 
Blood and urine samples for laboratory tests (hematology, serum biochemistry, and urinalysis) 
will be collected as specified in  Table 1-1. Clinical laboratory specimens will be analyzed by a 
central licensed and accredited laboratory facility according to the laboratory’s standard operating procedures.  
If any of the laboratory parameters of interest show a significant shift from baseline, subjects will 
then be scheduled for an interim visit within 2 weeks to repeat the laboratory measurements. 
Non-fasting blood samples will be obtained at each visit for laboratory analysis of serum 
glucose, lipid panel, hsCRP, and PD study. 
No blood is to be collected for the PD study at Screening. 
Blood samples for serology assessment (HIV, HBsAg, Anti-HBc, and HCV) will be obtained at 
Visit 1 (Screening).  
Lymphocyte subsets and antibody titer  will be collected for safety assessments per  Table 1-1. 
The routine clinical laboratory tests to be performed are provided in Table 7 -2. 
The investigator may collect additional blood or urine samples to repeat any laboratory test that was abnormal post-dosing, or was within normal limits at Baseline, and is considered clinica lly 
significant. Abnormal laboratory results at the last scheduled visit may require additional 
collection of samples on an “as needed” basis until: a) the values return to the baseline value, b) the values are within normal limits, c) the values are  clinically stable, or d) the investigator 
determines that further follow -up is unnecessary. The investigator will record the date and time 
of all additional samples collected. If the investigator establishes a clear explanation for the  
laboratory abnormality, h e/she will record this explanation in the eCRFs . 
Blood will also be collected and evaluated for PD study per Table 1-1. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 54 - Table 7-2 Routine Clinical Laboratory Assessments 
Hematology  
• Platelet Count   RBC Indices : Automated WBC Differential:  
• RBC Count  • MCV • Neutrophils  
• WBC Count (absolute)  
• Lymphocytes (absolute)  
• Neutrophils (absolute) 
• Monocytes (absolute)  • MCHC  
• MCH • Lymphocytes  
• Monocytes  
• Eosinophils  
• Basophils  
• Hemoglobin    
• Hematocrit  
• Lymphocyte subset (collected and will be assessed )  
• Antibody titer (collected and stored with assessment done as required)  
 
Chemistry   
• Sodium • Creatine Kinase • Cholesterol   
• Potassium  • Alkaline Phosphatase  • Triglycerides  
• Chloride • GGT • HDL Cholesterol  
• Bicarbonate  • LDH • LDL Cholesterol  
• BUN  • Total Bilirubin  • Calcium 
• Creatinine  • Direct Bilirubin  • Phosphorus  
• AST (SGOT)  • Total Protein  • Uric Acid  
• ALT (SGPT)  • Glucose (non-fasting) • Magnesium  
 • Albumin • Creatinine Clearance  
   
Routine Urinalysis   
• Appearance, color  
• pH, specific gravity  
• Glucose, blood, bilirubin, leukocyte esterase, ketones, nitrates  
• Urine protein, urine creatinine, protein:creatinine ratio  
• Microscopic examination (if indicated per clinical laboratory standards)  
 
Serology (Visit 1/Screening only)  
• HIV 
• HBsAg and Anti -HBc 
• HCV 
 
7.5.4 Pregnancy Testing  
All female subject s will undergo a serum pregnancy test  at the screening visit. Female subjects of 
child-bearing potential will undergo  a urine pregnancy test at the baseline visit before the subject 
is randomized. If either pregnancy test  is positive, the subject will not be permitted to enroll in 
the study. 
Urine pregnancy tests will be performed as per the study schedule.  At the investigator’s 
discretion, additional testing for pregnancy may be performed for verification purposes. The 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 55 - pregnancy tests must have a sensitivity of at least 25 mIU/mL.  If there is a suspicion of 
pregnancy at any time du ring the study, a urine sample will be obtained and tested . Should a 
subject become pregnant during the study, treatment must be immediately discontinued. Subjects 
should continue with non- treatment and/or follow -up visits.  
All pregnancies should be immed iately reported to the sponsor/Contract Research Organization 
(CRO)/Medical Monitor and followed through to resolution (ie, delivery, miscarriage, or 
abortion). The report should be submitted within the same timelines as an SAE (within 24 hours 
of knowledge), although a pregnancy per se is not considered an SAE. 
7.5.5 Vital Signs  
Measurements of vital signs, including blood pressure, pulse rate, and respiratory rate, will be 
taken at every visit with the subject seated.  
7.5.6 Physical Examination 
A complete physical ex amination  including assessments of the head, eyes, ears, nose, throat, 
skin, neck (including thyroid), lungs, cardiovascular, abdomen, lymph nodes and extremities will be obtained at Screening . Weight (in kg), height (in cm) and waist circumference (in cm)  will 
also be measured.  
An abbreviated  physical exam including changes since the Screening Visit with focus on 
previously noted abnormalities in organ systems, including skin, will be completed at Baseline/Visit 2 and at all post-Baseline visits . Weight will also be measured .  
Abnormalities noted during the Screening or Baseline physical exams  should be recorded on the 
Medical History eCRFs.  Any abnormalities noted on the physical exam following the first dose 
of study drug should be recorded as a n AE, as appropriate.  
7.5.7 Electrocardiogram  
A 12-lead electrocardiogram ( ECG) will be recorded at the visits specified in  Table 1-1. 
7.6 Appropriateness of Measurements  
The methodology used in this study to determine efficacy and safety are the standardized and 
most widely accepted methods for evaluating safety and efficacy in studies of plaque psoriasis. 
8. STATISTICAL METHODS AND DETERMINATION OF  SAMPLE SIZE 
STATISTICAL AND ANALYTICAL PLANS  
8.1 General Considerations  for Data Analysis 
The methodology presented in this section represents a brief overview of the statistical methods that will be fully detailed in the statistical analysis plan (SAP).  The SAP will be f inalized before 
the database is locked and unblinded. Any changes to the methods described in the final SAP will be described and justified in the clinical study report.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 56 - Study sites will be pooled into analysis centers for the efficacy analyses. The composition of 
pooled analysis centers will be finalized before the database is locked and unblinded. 
All statistical analyses will be performed using SAS statistical software (Version 9.2 or above) . 
Statistical significance will be tested at the 2 -sided 5% level. Subgroup analyses (eg, prior 
biologic use) may be performed. 
Data collected in this study will be presented using summary tables, figures, and subject data 
listings. Summary tables will present data by treatment group and, if applicable, by time of 
collection. Continuous variables will be summarized using descriptive statistics, specifically the 
mean, median, standard deviation, minimum and maximum. Categorical variables will be summarized by frequencies and percentages. Figures will be used to support the presentation of 
certain data.  
8.2 Sample Size  and Power Considerations 
It was determined that a sample size of 100 subjects per treatment group would detect a 
significant difference in proportion of PASI -75 and IGA responders from Baseline to Week  24 
between each dose group of PPC -06 and placebo group, assuming a 15% response rate for the 
placebo group and 45% for PPC -06 at Week  24. To provide sufficient evidence of t reatment 
effect, both PASI and IGA based response rate have to be rejected at the same significance level. 
The hypothesis testing for the 3 dose groups will be conducted sequentially from high to low 
dose; therefore, the 2 -sided Type  I error rate from a chi -squared test remains at the 0.05 level. 
Assuming 50% dropout rate, about 100 subjects per treatment arm will be randomized to get 
approximately 50 completers in each treatment arm. The total sample size of 400 subjects will 
yield at least 84% power for hypothesis testing of the co-primary endpoints of a difference in PASI-75 and IGA responders from Baseline to Week  24 between PPC -06 doses and placebo. 
8.3 Analysis Populations 
The analysis populations include the following:  
• The safety population will include all subjects who receive at least one dose of IP. The 
safety population is the population used for all safety analyses. 
•  Full Analysis Set (FAS) - All randomized subjects who receive at least one dose of 
investigational product and have at least one post dose efficacy assessment. The FAS 
population will be the primary population for the efficacy analyses.  
 
• The Per Protocol (PP) population will include subjects in the FAS  population who 
complete the study without any major protocol violations . The composition of the PP 
population will be determined and documented in blind reviews of t he database 
conducted prior to unblinding the study database.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 57 - 8.4 Background and Demographic Characteristics  
Demographic data that will be summarized include age, gender, race, weight, waist 
circumference,  and BMI . Baseline characteristics assessments include the pre -dosing 
assessments for the following variables: PASI, BSA, and IGA. Demographic and Baseline 
characteristics will be summarized by treatment group.  
Any variables found to be imbalanced across treatment groups at Baseline may be included as covariates or be used as subgroup levels in exploratory efficacy analyses . Full details of the 
Baseline analyses will be described in the SAP.  
8.5 Study Medication/Visit Compliance  
The number of doses received by each subject and the number of days exposed to study medication  will be summarized by treatment group  and study period (titration, treatment, overall) 
using summary statistics (mean, standard deviation [SD], median, minimum, and maximum), and 
categorically.  
The percent of subjects compliant with study medic ation at each visit will be presented by study 
period and overall. 
Following are the compliance parameters:  
• Total number of tablets taken during the titration period (Week 1-5), defined as number 
of dispensed tablets from blister wallets minus number of re turned tablets from blister 
wallets. 
• Total number of tablets taken during the treatment period (Week 6 – 24), defined as total 
number of dispensed tablets from bottles minus total number of returned tablets from bottles. 
• Number of tablets taken per bottle during the treatment period (Weeks 6 - 24), defined as 
number of dispensed tablets per bottle (total of 4 bottles per visit) minus number of returned tablets per bottle (total of 4 bottles per visit). 
• Total number of tablets taken, defined as the summation of number of tablets taken during the titration and the treatment period.   
• Percent compliance will be calculated as the number of tablets taken divided by the 
expected number of tablets, as defined for the titration period, treatment period and overall. 
• Subject compliance, defined as 80% - 120% (inclusive) in percent. If the percentage of study medication compliance is unknown, the subject is assumed to be non- compliant 
with study medication.  
• The average daily dose of IP received can be calculated as the number of tablets divided 
by the number of days exposed to study medication. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 58 - • The average daily dose of IP received by each subject will be summarized by visit, 
treatment group using summary statistics (mean, SD, median, minimum, and maximum), 
for the overall period. 
8.6 Prior and Concomitant Therapy  
Prior and concomitant medication information for all randomized subjects will be presented in a 
by-subject listing . Summary tables will be presented by Anatomical Therapeutic Chemical 
Classification System (ATC) the rapeutic category and product based on WHO- DD coding . 
8.7 Analysis of Efficacy  
8.7.1 Co-Primary Efficacy Endpoint(s) 
The co-primary efficacy endpoints are as follows: 
• The proportion of subjects who achieve a reduction of 75% or greater from Baseline in 
the Psoriasis  Area and Severity Index (PASI -75) at the end of Week 24 
• The proportion of subjects who achieve an IGA score of clear or almost clear ( IGA score 
0 or 1) at the end of Week 24 
The null hypothesis to be tested for the primary efficacy endpoint is that the proportion of 
subjects who achieve PASI -75 and IGA success is not different between the subjects treated with  
PPC-06 and placebo. The alternative hypothesis is that the proportion of subjects who achieve 
PASI-75 and IGA success at Week 24 for placebo is diff erent from PPC-06. Each of the PPC -06 
doses will be compared with placebo separately .  
Each of the dichotomized endpoints, PASI -75 response (Yes/No) and the IGA response, at Week 
24 will be analyzed using a logistic regression model with treatment, baseline BMI , and pooled 
analysis center as factors. Additional factors may be included in the models. Each of the PPC-06 
doses will be compared to placebo separately .  
To provide sufficient evidence of treatment effect, both PASI and IGA based response ra te have 
to be rejected at the same significance level. The hypothesis testing for the 3 dose groups will be 
conducted sequentially from high to low dose; therefore, the 2- sided Type I error rate from a chi -
squared test remains at the 0.05 level. 
8.7.2 Secondary Efficacy Endpoints 
The secondary endpoints are the following 
• Percent change from Baseline in Total PASI Score by Visit; 
• Proportion of subjects who achieve PASI- 50 and PASI-75 by Visit; 
• Proportion of subjects who achieve an IGA score of clear or almost clea r by Visit; 
• Absolute and percent change from Baseline in percent of affected BSA by Visit; 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 59 - • For applicable subjects, change from baseline by visit in NAPSI of the target fingernail, 
PSSI, and PP P GA; 
• Absolute and percent change from baseline in pruritus NRS by visit 
• Time to achieving a PASI 75 response; 
• Time to achieving an IGA score of 0 or 1 ; 
The quality of life endpoints are the following: 
• Change from Baseline by Visit in DLQI Total Score , SF-12, QIDS-SR16, and WPAI: 
PSO; 
• Summary of HEOR questions by visi t; 
Secondary efficacy variables will be analyzed as follows:   
Categorical secondary efficacy endpoints will be summarized at each visit using the number and percentage of subjects within each category for each treatment group. A same logistic regression mo del as used for the primary endpoint will be performed including treatment, 
baseline BMI , and pooled analysis center as factors. Additional factors may be included in 
the models. Each treatment will be compared to placebo separately as described in the primary analysis.  
Continuous secondary efficacy endpoints will be summarized descriptively and analyzed 
using an Analysis of Variance (ANOVA) including factors for treatment , baseline BMI , and 
pooled analysis center. Each treatment will be compared to placebo separately as described in 
the primary analysis. Additional factors along with interaction terms may be included in the 
models. 
All secondary efficacy analyses will be performed on the FAS  and PP populations. Subgroup 
analyses may also be performed.  
All QoL endpoints will be summarized by visit and treatment group using descriptive 
statistics. 
8.7.3 Handling of Missing Values/Censoring/Discontinuations  
The primary population for all efficacy analyses will be the FAS population.  
For the analyses of the primary endpoints (PASI-75 and IGA) based on the FAS population, 
several methods will be used to impute missing data, including , multiple imputation (MI),  
modified non-responder imputation (mN RI), and last -observation- carried forward (LOCF) .  MI 
will be the primary imputation method . Sensitivity analyses using LOCF and m-NRI will be 
performed to assess the robustness of alternate imputation assumptions. In particular, subjects 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 60 - who used rescue m edications or who discontinue due to unsatisfactory therapeutic effect  will be 
included in PP population. These subjects will be considered as treatment failures (i.e., non-
responder for both PASI-75 and IGA) for all time points after the initiation of rescue medications 
or subject discontinuation.  
MI:  Missing data will be imputed using multiple imputations. MI will be implemented for all 
subjects with missing data, including those who used rescue medications and those who 
discontinued due to unsatisfa ctory therapeutic effect.  
MI for missing PASI scores :  Intermittent missing values of PASI scores will be imputed 
separately for each  treatment group using the Markov Chain Monte Carlo (MCMC) method, generating 50 copies of the imputed dataset with monotonic missing pattern. For each of the 50 
datasets, missing values at scheduled visits (Weeks 4, 8, 12, 16, 20 and 24) will be imputed using 
a linear regression model. The imputations will include the following variables: baseline BMI, baseline PASI score, and PASI scores at the previous scheduled visits. SAS Proc MI will be 
used. Imputed PASI-75 response (Yes/No) will be derived for each imputed dataset.  
MI for missing IGA scores :  The imputation of post- baseline IGA scores will be performed 
following a s imilar approach as described for PASI scores. Intermittent missing IGA scores will 
be imputed separately for each treatment group using the Markov Chain Monte Carlo (MCMC) 
method where 50 copies of the dataset with monotonic missing pattern will be generat ed. For 
each of the 50 datasets, missing values at scheduled visits (Weeks 4, 8, 12, 16, 20 and 24) will be imputed using a logistic regression model including baseline BMI, baseline IGA score, and IGA scores at the previous scheduled visits. SAS Proc MI using the logistic regression method for monotone data will be used for the imputation. IGA Treatment Success status (Yes/No) will then be derived for each imputed dataset.  
The imputation of missing post- baseline BSA, NAPSI, and NRS scores will be performed  using 
a similar method as described for PASI. The imputation of missing post- baseline PSSI and PP 
PGA scores will be performed using a similar method as described for IGA. No imputation will be done to the health-related quality of life endpoints or safety endpoints and only observed 
values will be analyzed.  
mNRI: Subjects who used rescue medications or discontinued due to unsatisfactory therapeutic 
effect are considered as treatment failures (i.e., non -responder) for all time points after the 
intitaition of rescue medications or subject discontinuation.  Other missing data are not to be 
imputed and are to be kept as missing.  
LOCF: The last observed value will be carried forward for any subsequent missing values. 
Baseline values will not be carried forward.  
All QoL endpoints will be analyzed using the OC approach. No other imputations will be made 
unless otherwise specified. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 61 - Note that Early Termination visit data will be analyzed at the closest visit where data are not 
obtained. Full details will be provided in the SAP. 
8.7.4 Control of Multiplicity  
For the primary efficacy analysis (PASI -75 and IGA), each of the PPC -06 doses will be 
compared with placebo separately, sequentially from high to low dose to maintain the Type- I 
error rate. Therefore, no adjustments for multiplicity will be performed.  
8.8 Analysis of Safety 
The assessment of safety will be based mainly on the frequency of AEs and on the number of 
laboratory values that fall outside of predetermined ranges. Adverse events will be presented in 
data listings and summarized by frequency and severity for each treatment group. Laboratory and vital sign data will be presented in data listings . Abnormal laboratory findings will be presented. 
The analysis of safety will be described in th e SAP. 
8.8.1 Adverse events  
All AEs recorded during the study will be coded using the MedDRA coding dictionary. Adverse 
events that occurred after the first dose of study treatment are called TEAEs . The number and 
incidence of TEAEs will be summarized by MedDRA  System Organ Class (SOC)/Preferred 
Term (PT), intensity/severity, and relationship to study drug/treatment. Deaths and non- fatal 
SAEs will be listed by subject and tabulated by PT.  
8.8.2 Laboratory Evaluations 
Clinical laboratory values will be reported as complete listings of individual subject data. All laboratory values will be classified as normal, low, or high based on normal ranges supplied by the laboratory. Subjects with values outside the normal range will be flagged and summarized using shift tables. A separate listing and table will identify and summarize subjects with 
markedly abnormal values. For quantitative measures, observed and changes in clinical 
laboratory values will be analyzed descriptively by time of collection and treatment group . 
Lymphocy te counts will also be summarized by clinical response at PASI -50 and PASI-75 at 
Week 24. Lymphocyte counts and hs- CRP will also be plotted against PASI scores by visit and 
treatment.  
8.8.3 Vital Signs  
Change in vital sign data will be classified as normal, low,  high, based on a reference range. 
Observed and changes in vital sign parameters will be analyzed descriptively by time of collection and treatment group. Subjects with markedly abnormal changes will be listed and 
tabulated separately.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 62 - 8.8.4 Cardiac Assessments  
Data will be listed, notable values will be flagged, and any other information collected will be 
listed as appropriate. Subjects with markedly abnormal ECG changes will be listed and tabulated 
separately . Observed changes will be analyzed descriptively by time of collection and treatment 
group. 
8.8.5 Other Safety Assessments  
Concomitant medications/non-drug therapies taken during the study will be mapped to generic 
drug name and drug class . The number and percentage of subjects taking concomitant 
medications will be presented by treatment.  
8.9 Futility Analysis  
Futility analysis will be done when 50, 100 and 200 subjects complete the Double-Blind 
Treatment period. The analysis will be performed on blinded data.  
8.10 Protocol Deviations and Violations 
Protocol deviations will be identified on an ongoing ba sis and will be fully specified in  
InfoLink2 , Novella Clinical’s web-based Clinical Management System . Subjects with major 
protocol deviations will be excluded from the per protocol population. The assessment of all 
protocol deviations will be finalized prior to database lock. A subject with more than one major deviation per category will be counted  only once for that category. 
If there is discrepancy between protocol and Statistical Analysis Plan (SAP), SAP will 
supersede.  
9. CHANGES IN THE PLANNED STUDY  
9.1 Protocol Amendments  
With the exception of administrative changes, any changes or additions to this clinical study protocol require a written protocol amendment that must be approved by the sponsor, the CRO, and the investigator (s) before implementation. Amendments significantly affecting the safety of 
subjects, the scope of the investigation, or the scientific quality of the study, require additional approval by the IRB or IEC for each study center .  
These requirements for approval should in no way prevent any immediate action from being taken by the investigator or the sponsor in the interests of preserving the safety of all subjects 
included in the trial. If an immediate change to the protocol is felt to be necessary by the 
investigator  and is implemented for safety reasons, the sponsor should be notified and the 
IRB/IEC should be informed according to their reporting requirements. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 63 - 9.2 Termination or Suspension of the Study  
The sponsor reserves the right to terminate or suspend the study at any time . In case of premature 
termination or suspension of the study, the CRO project manager will promptly inform the 
investigator s, regulatory authorities, and IRBs /IECs about the premature termination or 
suspension, including the reason for termination . In terminating the study, the sponsor and the 
investigator  will ensure that adequate consideration is given to the protection of the subjects’ 
interests. 
10. DATA HANDLING AND RECORD KEEPING  
10.1 Recording of Data 
10.1.1 Source Documents  
Source data are all the information in original records and copies of original records of clinical 
findings, observations, or other activities in the study, which are necessary for the reconstruction and evaluation of the study. The identification of any data to be recorded directly on the CRFs is to be considered source data.  
Study data collection procedures must ensure that each data element can be traced with a high level of confidence from its originator or recorder to its representation in the study database and then to its place in the analysis and report of study results. Once recorded, the study data must be protected from unauthorized modification or deletion, and all authorized modifications and 
deletions must be securely linked in the permanent record with their author, time of change, and 
reason for change (ie, the audit trail must be maintained). 
The investigator will permit study -related monitoring, audit(s), IRB/IEC review(s) and 
regulatory inspection(s), with direct access to all the required source records. The principal investigator  will certify the data to be accurate and complete and will release the 
data for transmittal to the sponsor or CRO.  
Source records need to be preserved for the m aximum period of time permitted by local 
requirements  (see Section 10.2). For each subject  enrolled, the investigator will indicate in the 
source record(s) that the subject  participated in the study.  
10.1.2 Case Report Forms  
The primary data collection tool for the study is a n eCRF designed specifically for the study. For 
each subject enrolled in the study, an eCRF will be completed by the study coordinator and 
signed by the investigator  or his/her designee . Some QoL assessments as well as some 
investigator efficacy assessments will be recorded directly into an electronic device which will 
serve as the source document ; the data will then be transferred to the eCRF . 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 64 - The investigator will be responsible for ensuring the accuracy of all data entered in the e CRFs. 
All eCRFs are to be completed in a timely manner.  
Errors occurring in the eCRFs will be queried. Queries raised by data reviewers must be 
addressed by site personnel.  
On request, the investigator will provide the sponsor with additional data relating to the study, or 
copies of relevant source records, duly anonymized (ie , subject’s name is redacted ). 
10.2 Retentio n of Documents  
The United States Food and Drug Administration (FDA)/International Conference on Harmonisation ( ICH) regulations require all investigators participating in clinical drug trials to 
maintain detailed clinical data for one of the following periods: 
• at least 2 years following the date on which a Marketing Application is approved by the 
FDA/applicable  regulator y or health authority, or 
• 2 years after the sponsor notifies the investigator  that no further application is to be filed 
with the health authorities  
Similarly, ICH guidelines require that essential documents be retained until at least two years 
after the last approval of a marketing application in an ICH region and until there are no pending 
or contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the formal discontinuation of clinical development of the IP. European Union (EU) Directive 
2001/63/EC requires that essential docume nts be retained for at least 15  years after completion or 
discontinuation of the trial.  
To comply with these requirements, the investigator will not dispose of any records relevant to this study without either (1) written permission from the sponsor, or (2) providing an opportunity 
for the sponsor to collect such records. The investigator shall take responsibility for maintaining 
adequate and accurate hard copy source documents of all observations and data generated during this study, including any data clarification forms received from the sponsor. Such documentation 
is subject to inspection by the sponsor or its agents, the FDA and/or other regulatory agencies. 
11. QUALITY CONTROL AND QUALITY ASSURANCE  
11.1 Direct Access to Source Documents  
As specified in the investigator ’s agreement, the investigator  agrees to allow study-related 
monitoring, audit(s), IRB/IEC review(s) and regulatory inspection(s), with direct access to all the required source records, and to allocate his/her time and the time of his/her staff to the auditor/inspector to discuss findings and any issues.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 65 - 11.2 Monitoring Procedures  
The Clinical Study Monitor will contact and/or visit the investigator  site periodically to verify 
the adherence to the protocol, the maintenance of study- related source records, and the 
completeness and accuracy of all CRF entries compared to source data. The investigator  will 
cooperate with the study monitor to ensure that any discrepancies that may be identified are 
resolved. 
11.3 Audit  and Inspection  
The investigator will make all the study -related source data and records available to a quality 
assurance auditor mandated by the sponsor, or to domestic or foreign regulatory ins pectors, after 
reasonable notice. The main purposes of an audit or inspection are to confirm that the rights and 
well-being of the subject s have been adequately protected, and that all data relevant for the 
evaluation of the IP have been processed and repo rted in compliance with Good Clinical Practice 
(GCP)/ICH and applicable regulatory requirements. 
The investigator is to notify the sponsor/CRO immediately of any inspection by regulatory 
authorities or IRBs. 
12. ETHICS  
12.1 Ethical Conduct of the Study  
This study must be carried out in compliance with the protocol and the applicable laws and 
regulatory requirements of the FDA. The study must be conducted in accordance with the ethical 
principles originating from the Declaration of Helsinki and amendments and the ICH-GCP 
guidelines. 
12.2 Institutional Review Board (IRB) or Independent Ethics Committee (IEC)  
This protocol, the proposed ICF, and other information for subjects must be reviewed and 
approved by an IRB or IEC , before the start of the trial, in compliance with local regulations . 
This committee must also approve any amendments to the protocol, other than administrative 
ones, before initiation of the amendment procedures. 
12.3 Subject Information and Consent  
Before participation in the study, each subject is required to provide written consent to 
participate in the study . No study- specific procedures will be performed before a subject’s 
informed consent is obtained.  
12.4 Disclosure and Confidentiality  
12.4.1 Confidentiality of Study Documentation 
By signing the protocol, the investi gator agrees to keep all information provided by the sponsor 
in strict confidence and to request similar confidentiality from his/her staff and the IRB or IEC . 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 66 - Study documents provided by the study sponsor (ie, protocols, Investigators' Brochures, CRFs 
and other material) will be stored appropriately to ensure their confidentiality . The information 
provided by the sponsor to the investigator  may not be disclosed to others without direct written 
authorization from the sponsor , except to the extent necessary to obtain informed consent from 
subjects who wish to participate in the trial.  
12.4.2 Privacy of Individual Health Information  
The investigator will undertake to protect the privacy of all individually identifiable health 
information except as specifically autho rized by each individual subject through the written 
informed consent. The Informed Consent document will include a request of the subject’s consent to release the collected data for research purposes in such a way that the individual’s identity remains ma sked. While all data records will be identified by the corresponding subject 
number, the identity of the subject will be held in confidential source documents at the study site. All study personnel with access to this information are legally bound not to disclose such 
information . 
13. EMERGENCY PROCEDURES  
13.1 Emergency Unblinding  
Unblinding by study personnel should only be performed in emergencies where knowledge of 
the subject’s treatment assignment is essential for further management of the subject’s medical 
care. Unblinding a subject’s treatment assignment under any other circumstances will be considered a protocol violation.  
The investigator should assess the relationship of any AEs to administration of the IP prior to 
unblinding. 
The investigator is strongly encouraged to contact the study Medical Monitor before unblinding 
any subject’s treatment assignment, but must do so within 1 working day after the unblinding. The subject’s treatment code should not be communicated to the Medical Monitor or designee. The unblinding will be documented by the investigator.  
13.2 Reporting of Serious Adverse Events and Pregnancies  
13.2.1 Contact Person(s) and Number(s)  
Serious adverse events and pregnancies must be reported immediately (ie, not later than 24 hours 
after first knowledg e) to the sponsor’s designee, who then forwards the information to the 
Medical Monitor and the sponsor. 
The telephone and fax numbers of the study personnel to be contacted in the event of an SAE are 
provided to each site and are updated as required .  
Dr. Reddy’s Laboratories Ltd, Clinical Pharmacovigilance:  
Dr. Reddy’s Laboratories , SA 
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
- 67 - Shahida Hasan, MD 
Associate Dir ector 
Fax: 908-450-1510 / 1-877-445-3741 
Email: sae@drreddys.com  
13.2.2 Reportin
g Procedures  
Serious Adverse Events  
For each SAE, the investigator will complete a Serious Adverse Event Report Form and assess 
the relationship of each SAE to study treatment. The completed form(s) should be sent 
electronically to the  sponsor’s designee within 24 hours of first knowledge of the SAE.  
Follow-up reports regarding the status of the SAE and the subject’s subsequent course should be 
submitted until the SAE has subsided, the condition stabilized (in the case of persistent impairment), the subject receives alternative therapy, or the subject dies. T he form and fax 
confirmation will be retained . Contacts for reporting SAEs and other safety concerns are 
provided to each site.  
14. PUBLICATION POLICY
Written permission must be obtained from the Sponsor prior to submission to a publication or 
presentation. 
If the data merit, the Investigator and the Sponsor will discuss the preparation of a manuscript for 
publication in a peer-reviewed professional journal or an abstract for presentation, oral or written, to a learned society or symposium. Authorship should r eflect work done by the 
Investigators and personnel of the Sponsor, in accordance with generally recognized principles of scientific collaboration.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 68 - 15. REFERENCE LIST 
Altmeyer P, Hartwig R, Matthes U. Efficacy and safety profile of fumaric acid esters in oral  
long-term therapy with severe treatment refractory psoriasis vulgaris. A study of 83 patients. 
Hautarzt 1996;47:190-6.  
Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P, et al. Antipsoriatic effect 
of fumaric acid derivates: Results of a  multicenter double-blind study in 100 patients. J Am Acad 
Dermatol 1994;30:977- 81.  
Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 199 9;141:185–91. 
Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D. Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad 
Dermatol 2006 Apr;54(4 Suppl 1):S171-81.  
Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Score (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859–66. 
Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and 
psoriatic arthritis. J Autoimmun 2010;34:J314-J321. 
Davidovici B. Psoriasis and systemic inflammatory diseases: potential mechanistic links between 
skin disease and co -morbid conditions. J Invest Dermatol 2010;130:1785-96. 
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)— a simple practical measure for 
routine clinical use. Clin Exp Dermatol 1994;19:210–16. 
Fumaderm
® Summary of Product Characteristics, 2009. 
Fredriksson T, Pettersson U. Severe psoriasis—oral th erapy with a new retinoid. Dermatologica 
1978;157:238–44. Ghoreschi K, Weigert C, Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin 
Dermatol 2007;25:574-80. 
Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of mea sures of 
effect duration for psoriasis treatments. Arch Dermatol 2005;141:82-4. Harries MJ, Chalmers RJ, Griffiths CE. Fumaric acid esters for severe psoriasis: a retrospective 
review of 58 cases. Br J Dermatol 2005 Sep;153(3):549-51. 
Horn E. Association of patient -reported psoriasis severity with income and employment. J Am 
Acad Dermatol 2007;57;963-71. 
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 69 - Höxtermann S, Nüchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8 -
positive lymphocytes in psoriasis. Dermatology 1998;196(2):223-30. 
Investigator’s Brochure for PPC -06 (tepilamide fumarate) , Version 5, 2017.  
Krueger G. The impact of psoriasis on quality of life. Arch Dermatol  2001;137:280-84. 
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US 
adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009;60:218-24. [Erratum, J 
Am Acad Dermatol 2009;61:507.]  
Langner A , et al. Results of a phase 2 dose-ranging and safety extension study of a novel oral 
fumarate, BG00012, in patients with severe psoriasis. Am Acad Derm P2787 Feb 18-22, 2005. 
Laws P. Current and e merging systemic treatment strategies for psoriasis. Drugs 2012; 
72(14):1867-1880.  
Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe 
psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010 Apr; 31 (8): 1000-1006. Epub 2009 Dec 27.  
Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: Results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 
1997;138:456-60.  
Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumaric acid esters: 
Scientific background and guidelines for therapeutic use. The Germ an Fumaric Acid Ester 
Consensus Conference. Br J Dermatol 1999;141:424-9.  
Mrowietz U, Spellman MC . Efficacy and safety of a novel formulation of an oral fumarate, BG-
12, in patients with moderate to severe plaque psoriasis: results of a phase III study. J AM 
ACAD Dermatol  Mar 2005 ;182. 
Nast A, Boehncke WH, Mrowietz U, et al. S3 — guidelines on the treatment of psoriasis vulgaris (English version): update. J Dtsch Dermatol Ges 2012;10:Suppl 2:S1-S95. 
Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M, et al. S3 -Leitlinie zur 
Therapie der Psoriasis vulgaris. J German Soc Dermatol 2006;4:51-5. 
National Psoriasis Foundation. (n.d.). About Psoriasis. Retrieved 2013, from National Psoriasis 
Foundation: http://www.psoriasis.org/about/psoriasis  
Nestle F, Kaplan D, Barker J. Psoriasis. N ew Engl J Med 2009;361:469-509. 
Ormerod AD, Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol 2004;150:630-2.  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 70 - Palfreeman A. New developments in the management of psoriasis and psoriatic arthritis: a focus 
on apremilast. Drug Design, Development and Therapy 2013;3(7):201-10.  
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, Augustin M, Szepietowski JC, Ständer S. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012 Sep;92(5):502-7. doi: 10.2340/00015555-1246. 
Prodanovich S. Association of psoriasis with coronary artery, cerebrovascular, and peripheral 
vascular disease and mortality. Arch Dermatol 2009;145:700-3. 
Reich A, Heisig M, Szepietowski JC. Visual Analogue Scale as a validated assessment of 
pruritus intensity. Acta Derm Venereol 2009; 89: 688.  
Roll A, Reic h K, Boer A. Use of fumaric acid esters in psoriasis. Indian J Dermatol Venereol 
Leprol 2007;73:133-7 Schweckendiek W. Heilung von Psoriasis vulgaris. Med Monatsschr 1959;13:103-4. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a 
substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004;9:136-9. 
Sterry W. Biological therapies in the systemic management of psoriasis: International Conse nsus 
Conference. Br J Dermatol 2009;151(Suppl 69):3-17. TECFIDERA [package insert]. Cambridge, MA:  Biogen Inc.; 2017 Wain EM, Darling MI, Pleass RD, Barker JN, Smith CH. Treatment of severe, recalcitrant, 
chronic plaque psoriasis with fumaric acid esters:  a prospective study. Br J Dermatol 2010 Feb 
1;162(2):427-34. doi: 10.1111/j.1365-2133.2009.09267.x. Epub 2009 Jun 12. 
Zanni G. Psoriasis: Issues far more serious than c osmetic. The Consultant Pharmacist 
2012;27(2):86-96.  
  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 71 - 16. APPENDICES  
Appendix 1 Psoriasis Area and Severity Index (PASI)  
Appendix 2 Nail Psoriasis Severity Index  (NAPSI)  
Appendix 3 Psoriasis Scalp Severity Index  (PSSI) 
Appendix 4 Palmoplantar Psoriasis Physician’s Global Assessment (PP  PGA) 
 
Appendix 5 Quality of Life Assessment: Dermatology Life Quality Index  (DLQI) 
Appendix 6 Quality of Life Assessment: SF-12 
Appendix 7 Quick Inventory of Depressive Symptomatology (Self-Report) 
Appendix 8 Work Productivity and Activity Impairment Questionnaire: Psoriasis 
(WPAI:PSO)  
Appendix 9 Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. 
Published: 28 May 2009 (v4.03: 14 June 2010) 
Appendix 10 Bristol Stool Chart 
 
  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 72 - Appendix 1 Psoriasis Area and Severity Index (PASI) 
PASI consists of two major steps:  
1) calculating the BSA  covered with lesions and  
2) assessment of the severity of lesions , including assessing the erythema (redness), induration 
(thickness) and scaling.   All calculations are combined into a single PASI score in the range of 0 (no psoriasis on the body) and up to 72 (the most severe case of psoriasis).   Intensity  A representative area of psoriasis is selected for each body region. The intensity of redness, thickness and scaling of the psoriasis is assessed as none (0), mild (1), moderate (2), severe (3) or very severe (4).  
 Calculation for intensity  The three int ensity scores are added up for each of the four body regions to give subtotals A1, 
A2, A3, A4.  Each subtotal is multiplied by the body surface area represented by that region.  A1 x 0.1 gives B1  A2 x 0.2 gives B2  A3 x 0.3 gives B3  A4 x 0.4 gives B4   Area  
The percentage area affected by psoriasis is evaluated in the four regions of the body (see below). In each region, the area is expressed as nil (0), 1- 9% (1), 10 -29% (2), 30-49% (3), 50-
69% (4), 70- 89% (5) or 90 -100% (6): 
 Head and neck  
Upper limbs  Trunk  Lower limbs  
 Calculations for area  Each of the body area scores is multiplied by the area affected.  
B1 x (0 to 6)= C1  B2 x (0 to 6)= C2  B3 x (0 to 6)= C3  B4 x (0 to 6)= C4   Total score  
The PASI score is C1 + C2 + C3 + C4   
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 73 - Appendix 2 Nail Psoriasis Severity Index  (NAPSI)  
The Nail Psoriasis Severity Index (NAPSI)  is a numeric, reproducible, objective, simple tool 
for evaluation of nail psoriasis. This scale is used to evaluate the severity of nail bed psoria sis 
and nail matrix psoriasis by area of involvement in the nail unit 
• NAPSI is used to assign a score to each nail for nail bed and nail matrix psoriasis (Rich 
2003): 
• nail plate is divided into quadrants by imaginary longitudinal and horizontal lines  
o nail plate is assessed for nail matrix psoriasis by the presence of any feature of 
nail matrix psoriasis, including nail pitting, leukonychia, red spots in the lunula, 
and crumbling in each quadrant of the nail 
o nail bed psoriasis is assessed by the presence of  any features of nail bed psoriasis, 
including onycholysis, oil drop (salmon patch) dyschromia, splinter hemorrhages, and nail bed hyperkeratosis in each quadrant of the nail 
o score is 0 if the findings are not present, 1 if they are present in 1 quadrant of the nail, 2 if present in 2 quadrants of a nail, 3 if present in 3 quadrants of a nail, and 4 if present in 4 quadrants of a nail  
 thus each nail has a matrix score (0 -4) and a nail bed score (0 -4), and the 
total nail score is the sum of those 2 individual scores (0- 8) 
• All fingernails will be scored at Baseline and a target nail will be selected, which will be 
the nail with the highest score. Only the target nail will be evaluated at subsequent visits.  
Reference:  
Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003 Aug;49(2):206-12.  
Cassell SE et al. The modified Nail Psoriasis Severity Index: validation of an  instrument to 
assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34: 123-9. 
 
 
  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 74 - Appendix 3 Psoriasis Scalp Severity Index  (PSSI)   
 
Psoriasis Scalp Severity Index (PSSI)  
 
Descriptor  Score Range Score 
Erythema (E)  0 - 4  
Induration (I)  0 - 4  
Scaling (S)  0 - 4  
Area scoring  0 - 6  
 
 
Descriptors for severity:  
0= None  
1= S light  
2= M oderate  
3= M arked  
4= S evere  
 Area scoring criteria:  
1= >0 to  <10%, 2 = 10 to  <30%, 3= 30 to  <50%, 4= 50 to <70%, 5= 70 to < 90%, 6= 90 to 100%  
 Final score = (E+I+S) multiplied by area score  
 
 
  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 75 - Appendix 4 Palm oplantar Psoriasis Physician’s Global Assessment (PP  PGA)  
 
Palmoplantar Psoriasis Physician’s Global Assessment (PP  PGA) of Disease Severity  
 
Score  Grade  Definition  
0 Clear No signs of plaque psoriasis  on hands and/or feet  
1 Almost 
clear  Just perceptible erythema and just perceptible scaling on the hands 
and/or feet.  
2 Mild Light pink erythema with minimal scaling with or without pustules 
on hands and/or feet  
3 Moderate  Dull red, clearly distinguishable erythema with diffuse scaling and 
thickening of the skin, with or without fissures and with or without 
pustule formation on the hands and/or feet.  
4 Severe Deep, dark red erythema with clearly obvious diffuse scaling and 
thickening and numerous fissures with or without pustule formation 
on hands and/or feet.  
 
 
  
Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 76 - Appendix 5 Quality of Life Assessment: Dermatology Life Quality Index (DLQI) 
 

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 77 - Appendix 6 Quality of Life Assessment: SF -12 
 
 
 
 
 

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 78 -  
 
 
  

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 79 -  
 
 
 
  

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 80 - Appendix 7 Quick Inventory of Depressive Symptomatology (Self- Report)  
 
 

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 81 -  
 
 

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 82 - Appendix 8 Work Productivity and Activity Impairment Questionnaire: Psoriasis V2.0 
(WPAI:PSO)  
 
 

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 83 -  
 
 
 
 
 
 
 
 

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 84 - Appendix 9 Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 
 Published: 28 May 2009 (v4.03: 14 June 2010) 
 
 
Investigations (page 42): 
 
 
 
Diarrhea (page 13): 
 
 
 

Dr. Reddy’s Laboratories , SA  
Amendment 2  Clinical Study Protocol  PPC-06-CD-004 
26 October 2018  
 
- 85 - Appendix 10 Bristol Stool Chart 
 
 
